<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Immunol Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J Immunol Res</journal-id>
<journal-id journal-id-type="publisher-id">JIR</journal-id>
<journal-title-group>
<journal-title>Journal of Immunology Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">2314-8861</issn>
<issn pub-type="epub">2314-7156</issn>
<publisher>
<publisher-name>Hindawi</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31143780</article-id>
<article-id pub-id-type="pmc">6501133</article-id>
<article-id pub-id-type="doi">10.1155/2019/1603758</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cutting Edge: Probiotics and Fecal Microbiota Transplantation in Immunomodulation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-7384-8780</contrib-id>
<name>
<surname>Zeng</surname>
<given-names>Wenjie</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-8823-6488</contrib-id>
<name>
<surname>Shen</surname>
<given-names>Jie</given-names>
</name>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bo</surname>
<given-names>Tao</given-names>
</name>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0003-1878-5216</contrib-id>
<name>
<surname>Peng</surname>
<given-names>Liangxin</given-names>
</name>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-7684-4179</contrib-id>
<name>
<surname>Xu</surname>
<given-names>Hongbo</given-names>
</name>
<xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Nasser</surname>
<given-names>Moussa Ide</given-names>
</name>
<xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-5225-9282</contrib-id>
<name>
<surname>Zhuang</surname>
<given-names>Quan</given-names>
</name>
<email>zhuangquansteven@csu.edu.cn</email>
<xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="I6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0002-2884-0736</contrib-id>
<name>
<surname>Zhao</surname>
<given-names>Mingyi</given-names>
</name>
<email>36163773@qq.com</email>
<xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref>
</contrib>
</contrib-group>
<aff id="I1">
<sup>1</sup>Transplantation Center of the 3rd Xiangya Hospital, Central South University, Changsha, Hunan 410013, China</aff>
<aff id="I2">
<sup>2</sup>Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China</aff>
<aff id="I3">
<sup>3</sup>Pediatric Department of the 3rd Xiangya Hospital, Central South University, Changsha, Hunan 410013, China</aff>
<aff id="I4">
<sup>4</sup>Department of Surgery of the 3rd Xiangya Hospital, Central South University, Changsha, Hunan 410013, China</aff>
<aff id="I5">
<sup>5</sup>Guangdong Cardiovascular Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong 510100, China</aff>
<aff id="I6">
<sup>6</sup>Research Center of National Health Ministry on Transplantation Medicine, Changsha, Hunan 410013, China</aff>
<author-notes>
<fn fn-type="other">
<p>Guest Editor: Syed Moin</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>16</day>
<month>4</month>
<year>2019</year>
</pub-date>
<volume>2019</volume>
<elocation-id>1603758</elocation-id>
<history>
<date date-type="received">
<day>29</day>
<month>11</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>1</day>
<month>4</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2019 Wenjie Zeng et al.</copyright-statement>
<copyright-year>2019</copyright-year>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<abstract>
<p>Probiotics are commensal or nonpathogenic microbes that confer beneficial effects on the host through several mechanisms such as competitive exclusion, antibacterial effects, and modulation of immune responses. Some probiotics have been found to regulate immune responses via immune regulatory mechanisms. T regulatory (Treg) cells, T helper cell balances, dendritic cells, macrophages, B cells, and natural killer (NK) cells can be considered as the most determinant dysregulated mediators in immunomodulatory status. Recently, fecal microbiota transplantation (FMT) has been defined as the transfer of distal gut microbial communities from a healthy individual to a patient's intestinal tract to cure some immune disorders (mainly inflammatory bowel diseases). The aim of this review was followed through the recent literature survey on immunomodulatory effects and mechanisms of probiotics and FMT and also efficacy and safety of probiotics and FMT in clinical trials and applications.</p>
</abstract>
<funding-group>
<award-group>
<funding-source>Central South University</funding-source>
<award-id>ZY20180988</award-id>
<award-id>ZY20180983</award-id>
<award-id>JY201524</award-id>
<award-id>JY201629</award-id>
</award-group>
<award-group>
<funding-source>Natural Science Foundation of Hunan Province</funding-source>
<award-id>2016JJ4105</award-id>
</award-group>
<award-group>
<funding-source>National Natural Science Foundation of China</funding-source>
<award-id>81500231</award-id>
<award-id>81700658</award-id>
</award-group>
</funding-group>
</article-meta>
</front>
<body>
<sec id="sec1">
<title>1. Introduction</title>
<p>Probiotics were defined in 2002 by experts from the Food and Agriculture Organization of the United Nations and the World Health Organization, and the definition was updated by the International Scientific Association in 2013 [<xref ref-type="bibr" rid="B1">1</xref>]. The definition states that probiotics are “live strains of strictly selected microorganisms which, when administered in adequate amounts, confer a health benefit on the host.” Probiotic products are commonly known to be microecological preparations and are used to improve the structure of intestinal flora, inhibit the growth of harmful microorganisms, and enhance the immunity of the human body. To be considered microecologics, probiotics must satisfy the following conditions [<xref ref-type="bibr" rid="B2">2</xref>]: be live microorganisms; stay alive and stable before use after culture, production, and storage; be resistant to gastric acid, bile, and trypsin, and remain alive to colonize and proliferate in the intestinal tract; be scientifically proven to be beneficial to the host; and be proven to be safe and reliable or an member of the original intestinal microflora. Currently, the extensively studied and developed probiotics include the related bacteria of <italic>Lactobacillus</italic>, <italic>Bifidobacteria, Escherichia coli (E. coli),</italic> and <italic>Enterococcus</italic> and some yeasts [<xref ref-type="bibr" rid="B3">3</xref>].</p>
<p>Currently, as a means of intestinal microecological regulation in addition to microecological preparations, fecal microbiota transplantation (FMT) has become popular in recent years. FMT refers to the transplantation of functional bacteria in the feces of healthy donors into the gastrointestinal tract of the patient to restore the balance of the intestinal microecology, which subsequently treats diseases associated with disorders of intestinal microorganisms. As far back as traditional medical treatments in the fourth century of China, there have been relevant records of FMT treatment [<xref ref-type="bibr" rid="B4">4</xref>]. In the era of modern medicine, the earliest report of FMT was in 1958. Eiseman et al. successfully used FMT to treat a case with pseudomembranes [<xref ref-type="bibr" rid="B5">5</xref>]. The first report of FMT application in the treatment of <italic>Clostridium difficile</italic> (<italic>C. difficile)</italic> infection (CDI) was in 1983 [<xref ref-type="bibr" rid="B6">6</xref>]. In 2010, the United States recommended FMT as a treatment plan for CDI in their clinical guidelines [<xref ref-type="bibr" rid="B7">7</xref>]. FMT has now been deemed the primary therapy for refractory and relapsed CDI. In recent years, FMT has become a research focus on biomedicine and clinical medicine. FMT has also been clinically applied to inflammatory bowel disease (IBD), irritable bowel syndrome, chronic functional constipation, intestinal cancer, foodborne allergic gastroenteropathy, and so on [<xref ref-type="bibr" rid="B8">8</xref>], and researchers have achieved a certain clinical efficacy. Recently, some studies have shown that there is a very strong potential application for FMT in the field of nongastrointestinal diseases, such as treating arteriosclerosis, metabolic syndrome, diabetes, hepatic encephalopathy, neurodegenerative diseases, among others [<xref ref-type="bibr" rid="B9">9</xref>].</p>
</sec>
<sec id="sec2">
<title>2. Probiotics and the Immune System</title>
<p>Relevant studies on the mechanism of probiotics mainly focus on the intestinal tract. However, the effect of probiotics is not confined to the initial infection site, and probiotics can work throughout the entire body via the immune system. In gut-associated lymphoid tissues (GALT), probiotic and antigen substances from its metabolites are phagocytized or internalized by M cells to form endosomes. Antigens in M cells are rapidly released and taken in by dendritic cells (DCs), which can transport the antigens to local lymph nodes and then activate naive T and B cells to differentiate into different effector subpopulations, initiating the release of the corresponding cytokines and displaying different immune functions.</p>
<p>A number of studies show that the mechanisms of probiotics include (1) enhancement of the chemical and biological barriers in the intestinal tract as well as regulation of the balance of intestinal flora. Through a space-occupying effect, competition, or antagonism [<xref ref-type="bibr" rid="B10">10</xref>–<xref ref-type="bibr" rid="B14">14</xref>], and by secreting antibacterial or bactericidal substances (e.g., bacteriocin), increasing digestive enzyme activity, producing organic acid, and so on [<xref ref-type="bibr" rid="B15">15</xref>], probiotics can exert an antibacterial effect, maintain the function of intestinal epithelial cells, prevent pathogenic bacteria adhesion, and inhibit the growth of pathogenic bacteria. (2) Through increasing the synthesis of tight junction proteins between epithelial cells [<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>], probiotics stimulate and promote the expression and secretion of mucous glycoproteins [<xref ref-type="bibr" rid="B18">18</xref>], enhance the integrity of intestinal epithelial cells, strengthen the mechanical barrier function of the intestinal tract, and prevent the displacement of intestinal bacteria and endotoxins. (3) Probiotics regulate innate and adaptive immunity, including promoting the development and maturation of the immune system [<xref ref-type="bibr" rid="B19">19</xref>], enhancing the viability of macrophages and natural killer (NK) cells [<xref ref-type="bibr" rid="B20">20</xref>], stimulating the secretion of secretory immunoglobulin A (sIgA) [<xref ref-type="bibr" rid="B21">21</xref>], activating related immune responses mediated by Toll-like receptor (TLR) and nucleotide-binding oligomerization domain-containing protein- (NOD-) like receptors (NLR), regulating the T helper cell (Th)1/Th2 immune response, increasing the number of regulatory T cells (Treg) that secrete interleukin- (IL-) 10 and transforming growth factor (TGF)-<italic>β</italic>, and strengthening their function as well as reducing the level of allergen-specific IgE [<xref ref-type="bibr" rid="B22">22</xref>].</p>
<p>The role of probiotics in the immune system is complex. The immune stimulations induced by probiotics are manifested as an increase in the generation of immunoglobulins, enhanced activity of macrophages and lymphocytes, and stimulation of interferon- (IFN-) <italic>γ</italic>. Probiotics that inhibit the immune system are mainly embodied in their anti-inflammatory action. <xref ref-type="fig" rid="fig1"> Figure 1</xref> summarizes the dual function of probiotics in the immune system in in vitro and animal experiments.</p>
<p>Additionally, there is a mechanism behind positive and negative effects of probiotics on the immune system; yet, the exact molecular mechanisms for these commensal-host interactions are poorly described. Many immunomodulatory biologically active signaling molecules of probiotics are microbial-associated molecular patterns (MAMP) that interact with transmembrane host pattern recognition receptors (PRRs). TLR has been the most studied. In addition, extracellular C-type lectin receptors (CLRs) and intracellular NLR can also transmit signals by interaction with bacteria. <xref ref-type="table" rid="tab1"> Table 1</xref> summarizes the immunomodulatory components of the most common probiotics, <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic>. However, the molecular basis of these effector-mediated strain-specific probiotics needs to be thoroughly investigated.</p>
<p>Importantly, studies have shown that there are some differences in the physiology and metabolism between probiotic strains from different species and that their effects on the human body are different. Even the functions of different strains from the same species can vary greatly. Similarly, different doses of the same strain can produce different effects. Additionally, there are some differences in function in different hosts. Therefore, the functions of probiotics need to be verified at the strain level to clarify the efficacy of the strain.</p>
</sec>
<sec id="sec3">
<title>3. FMT and the Immune System</title>
<p>FMT can increase the microbial diversity of the intestines, maintain the intestinal microecological balance, and rebuild the function of the immune system. Related mechanisms may include (1) intestinal flora introduced from healthy donors that can maintain the intestinal epithelial integrity of patients, limit intestinal permeability, and inhibit intestinal epithelial cell apoptosis to reestablish the function of the intestinal barrier (this may be related to the mechanisms of the intestinal flora from donors that inhibit the adhesion between intestinal pathogens and intestinal epithelial cells (IECs), reduce the damage of IECs, and increase the production and expression of mucosal IgA and mucin by colonizing resistance and producing immunomodulatory molecules and bacteriocin, etc.); (2) the intestinal flora of the donors can also fight against proinflammatory cytokines by directly synthesizing anti-inflammatory factors, reducing local and systemic inflammatory responses; (3) FMT restores the metabolism of secondary bile acids in the intestines, which makes the metabolism of secondary bile acids in the gastrointestinal tract of patients similar to that of donors; (4) competition or antagonism with pathogenic bacteria; and (5) improving insulin resistance. As a result, the patient's immunity is improved [<xref ref-type="bibr" rid="B23">23</xref>–<xref ref-type="bibr" rid="B27">27</xref>]. Applications in patients confirmed that the effects of FMT on the intestinal microflora of patients are long lasting and mostly safe, with few adverse effects [<xref ref-type="bibr" rid="B28">28</xref>]. In addition, FMT can improve anxiety and depression through mechanisms associated with the brain-intestine axis and improve the quality of life of patients [<xref ref-type="bibr" rid="B29">29</xref>].</p>
<p>With FMT, the intestinal flora of healthy donors may maintain the microenvironment of recipients and eventually reconstruct the recipient's intestinal ecological balance. The mechanisms can affect the disease processes of gastrointestinal and extraintestinal diseases by altering the mucosal cell gene expression, the intestinal mucosal immune function, the intestinal ecological environment, and body metabolism, which regulate the immune response, the inflammatory response, and the number and activity of neurotransmitters.</p>
</sec>
<sec id="sec4">
<title>4. Immunomodulatory Effects and Mechanisms of Probiotics and FMT</title>
<sec id="sec4.1">
<title>4.1. Th1/Th2 Balance</title>
<p>Th1 activates macrophages and neutrophils to promote an inflammatory response by secreting IL-2, IL-3, IFN-<italic>γ</italic>, and tumor necrosis factor- (TNF-) <italic>α</italic>. Th2 can secrete IL-4, IL-5, IL-6, IL-10, and IL-13 to activate mast cells and basophils to participate in allergic reactions. Many experiments have shown that probiotics can participate in the negative regulation of the immune system, such as anti-inflammation and antiallergy effects through affecting the Th1/Th2 balance.</p>
<sec id="sec4.1.1">
<title>4.1.1. Anti-inflammatory Effects</title>
<p>By oral administration of <italic>Lactobacillus plantarum</italic> (<italic>L. plantarum</italic>) A7 and <italic>Bifidobacterium animalis</italic> (<italic>B. animalis</italic>) PTCC 1631 to mice with autoimmune encephalomyelitis (EAE), Salehipour et al. found that naive T cells preferred to differentiate to Th2 cells because of increased production of transcription factor GATA3, which eventually led to the secretion of more IL-4 and IL-10 [<xref ref-type="bibr" rid="B30">30</xref>]. Mi et al. found that by orally administering <italic>Bifidobacterium infantis</italic> (<italic>B. infantis</italic>) to colorectal cancer mice induced by dimethylhydrazine, CD4+IL-17+ cells were reduced, resulting in decreased secretion of IL-2, IL-12, and IFN-<italic>γ</italic> from Th1 and Th17. Therefore, <italic>B. infantis</italic> could inhibit intestinal mucositis caused by chemotherapy drugs in colorectal cancer mice [<xref ref-type="bibr" rid="B31">31</xref>]. In addition, Rebeca's research showed that after feeding <italic>B. animalis</italic> ssp lactis CNCM-I2494 to low-level inflammatory mice induced by dinitrobenzene sulfonic acid, the number of Th2 cells and the levels of IL-4, IL-5, and IL-10 increased, which significantly improved the barrier permeability diseases [<xref ref-type="bibr" rid="B32">32</xref>]. Interestingly, oral administration of <italic>Clostridium butyricum</italic> (<italic>C. butyricum</italic>) CGMCC0313.1 to nonobese diabetic mice resulted in a significant reduction of Th1 and IFN-<italic>γ</italic> secretion in the spleen and an increase of Th2 and IL-4 [<xref ref-type="bibr" rid="B33">33</xref>]. Additionally, the serum IgE and IL-4 levels in atopic dermatitis mice were reduced by oral administration of <italic>Lactobacillus casei (L. casei)</italic> variety rhamnosus (LCR35). Moreover, the recovery of the Th1/Th2 balance improves intestinal flora [<xref ref-type="bibr" rid="B34">34</xref>]. In the study by Zheng et al., after feeding <italic>Bifidobacterium breve (B. breve</italic>) to colitis mice, the expression levels of IL-4, IL-5, IL-13, and IL-23 message ribonucleic acid (mRNA) in colon tissue increased. In subsequent studies, they also cocultured peripheral blood mononuclear cells (PBMCs) with <italic>B. breve</italic> and found that Th1 and Th17 decreased and Th2 and Treg increased [<xref ref-type="bibr" rid="B35">35</xref>].</p>
</sec>
<sec id="sec4.1.2">
<title>4.1.2. Antiallergic Effects</title>
<p>In the mouse model of ovalbumin (OVA) allergy, after oral administration of <italic>Lactobacillus bulgaricus</italic> (<italic>L. bulgaricus</italic>), <italic>Streptococcus thermophilus</italic> (<italic>S. thermophilus</italic>), and <italic>Lactobacillus paracasei</italic> (<italic>L. paracasei</italic>) ssp. paracasei CNCMI-1518, the number of Th2 cells and serum IgE decreased but serum IL-10 and IFN-<italic>γ</italic> increased in mice [<xref ref-type="bibr" rid="B36">36</xref>]. Similarly, after feeding <italic>Lactobacillus rhamnosus</italic> (<italic>L. rhamnosus</italic>) MTCC 5897 to OVA allergy mice, serum IL-4 decreased, whereas serum IFN-<italic>γ</italic> increased [<xref ref-type="bibr" rid="B37">37</xref>]. In a mouse model of whey protein hypersensitivity, oral administration of <italic>Lactobacillus acidophilus</italic> (<italic>L. acidophilus</italic>) and <italic>Bifidobacterium bifidum</italic> (<italic>B. bifidum</italic>) increased the levels of IFN-<italic>γ</italic>, IL-10, and IL-12 and decreased the level of IL-4 in the spleen [<xref ref-type="bibr" rid="B38">38</xref>]. Another experiment also showed that differentiation of Th1 increased in mesenteric lymph nodes (MLN) and the spleen and the serum histamine concentration decreased after oral administration of <italic>Bifidobacterium lactis</italic> (<italic>B. lactis</italic>), <italic>L. casei</italic>, <italic>L. rhamnosus</italic>, and <italic>L. plantarum</italic> to mice that were allergic to whey protein [<xref ref-type="bibr" rid="B39">39</xref>]. In addition, after feeding <italic>L. plantarum</italic> CJLP133 and CJLP243 to mice with allergic rhinitis caused by birch pollen (BP), the researchers found an increase in IFN-<italic>γ</italic> and decrease in IL-4, IL-5, and IL-13 in bronchoalveolar lavage fluid (BALF). At the same time, serum IL-4, IL-5, IL-13, IgE, and BP-specific IgG1 were also reduced [<xref ref-type="bibr" rid="B40">40</xref>].</p>
</sec>
</sec>
<sec id="sec4.2">
<title>4.2. Th17/Treg Balance</title>
<p>Probiotics can affect the Th17/Treg balance in the host immune system. When probiotics promote the differentiation of Th0 to Treg, the clinical effect is to negatively regulate the host immune system. Conversely, when probiotics promote the differentiation of Th0 to Th17, the clinical effect of probiotics is to positively regulate the host immune system. Treg can secrete TGF-<italic>β</italic>, IL-10, and IL-35 to participate in negative immune regulation. Th17 can secrete IL-17, IL-21, and IL-23 to participate in positive immune regulation. To provide a better understanding of this section, we summarized the available literature in <xref ref-type="fig" rid="fig2">Figure 2</xref>.</p>
<sec id="sec4.2.1">
<title>4.2.1. Anti-inflammatory Effects</title>
<p>In experiments with mice that had autoimmune encephalitis (EAE), Ménard et al. found that after feeding <italic>L. plantarum</italic> A7 and <italic>B. animalis</italic> PTCC 1631, the transcription factor Foxp3 of naive T cells increased, resulting in increased Treg differentiation and IL-10 production [<xref ref-type="bibr" rid="B41">41</xref>]. In addition, a study by Kwon et al. showed that IRT5 (a mixture of five probiotics) not only increased the levels of Treg and IL-10 in superficial lymph nodes of EAE mice but also reduced the amount of Th17 and secretion of IFN-<italic>γ</italic>, TNF-<italic>α</italic>, and IL-17 [<xref ref-type="bibr" rid="B42">42</xref>]. In the study by Mangalam et al., after feeding <italic>Prevotella histicola (P. histicola)</italic> to EAE mice, they found that the amounts of Th1 and Th17 decreased in the MLN and spleen, while the numbers of Treg, regulatory dendritic cells (DCreg), and suppressive macrophages increased [<xref ref-type="bibr" rid="B43">43</xref>]. Therefore, what is the possible pathway through which probiotics affect T cells? The study by Haghikia and colleagues provides an answer. They fed propionic acid (a metabolite of probiotic) to EAE mice and found that the JNK1 and p38 pathways in naive T cells were inhibited, leading to increased expression of Foxp3 and IL-10 mRNA as well as the promotion of the differentiation of naive T cells to Treg [<xref ref-type="bibr" rid="B44">44</xref>]. In addition, in experiments with colitis mice, Qiu et al. [<xref ref-type="bibr" rid="B45">45</xref>], Rodríguez-Nogales et al. [<xref ref-type="bibr" rid="B46">46</xref>], and Kanda et al. [<xref ref-type="bibr" rid="B47">47</xref>] found that probiotics promoted naive T cell differentiation to Treg and increased IL-10 secretion. Moreover, after giving oral <italic>L. acidophilus</italic> to colitis mice induced by dextran sulfate sodium (DSS), they found that not only Treg and IL-10 were increased but also IL-17 was decreased in the spleen. Additionally, the levels of IL-6, TNF-<italic>β</italic>, IL-1<italic>β</italic>, and IL-17 also decreased in colon tissue [<xref ref-type="bibr" rid="B48">48</xref>]. In the same model, Kim et al. found that activation of nuclear factor kappa B (NF-<italic>κ</italic>B) was inhibited and the endoplasmic reticulum (ER) pressure signal pathway was disturbed, leading to increased expression of IL-10 in the colon and increased levels of Th2 and Treg in the spleen [<xref ref-type="bibr" rid="B49">49</xref>]. In addition, studies have shown that after oral administration of a mixture of 12 probiotics, zinc, and CoQ10 to arthritic mice induced by collagen, Th17 decreased but Treg increased in the spleen. Moreover, the secretion of TNF-<italic>α</italic>, IL-1<italic>β</italic>, IL-6, and IL-17 decreased in the joint synovium. At the same time, the levels of IgG, IgG1, and IgG2a in the serum were reduced [<xref ref-type="bibr" rid="B50">50</xref>]. Cortes-Perez et al. found that after intragastric administration of <italic>L. casei</italic> BL23, the number of Foxp3+ROR<italic>γ</italic>t+T cells (type 3 Treg) increased [<xref ref-type="bibr" rid="B51">51</xref>]. By oral administration of <italic>Weissella cibaria (W. cibaria)</italic> WIKIM28 to mice with chronic inflammatory skin disease induced by 2,4-dinitrochlorobenzene, Lim et al. found that serum IgE decreased but Treg and IL-10 increased in MLN [<xref ref-type="bibr" rid="B52">52</xref>]. After feeding <italic>L. acidophilus</italic> to mice with ulcerative colitis, Chen et al. found that phosphorylation of STAT3 was inhibited, which subsequently caused increased secretion of IL-17 and TNF-<italic>α</italic> [<xref ref-type="bibr" rid="B53">53</xref>]. After feeding <italic>C. butyricum</italic> CGMCC0313.1 to autoimmune nonobese diabetic mice, <italic>α</italic>4<italic>β</italic>7+ Tregs increased in the pancreatic LN. This change restored the intestinal microbial disorders caused by diabetes [<xref ref-type="bibr" rid="B33">33</xref>].</p>
</sec>
<sec id="sec4.2.2">
<title>4.2.2. Antiallergic Effects</title>
<p>In the OVA-allergic mouse, Kim et al. showed that feeding <italic>L. rhamnosus</italic> (Lcr35) could result in increased Treg but decreased IL-4 and IL-17 in MLN, and the response of thymic stroma lymphocytes was weakened [<xref ref-type="bibr" rid="B54">54</xref>]. In addition, studies have shown that oral administration of <italic>Enterococcus faecalis (E. faecalis)</italic> FK-23 to OVA-allergic mice can reduce the number of IL-17-expressing CD4+ cells in the lungs, spleen, and intestine. Additionally, the total number of white blood cells and mast cells decreased in BALF [<xref ref-type="bibr" rid="B55">55</xref>]. Fu et al. discovered that after feeding <italic>Bacillus coagulans (B. coagulans)</italic> 09.712 to mice allergic to the prion troponin, the mTOR pathway was inhibited in naive T cells, which caused an increase in Foxp3 expression. Additionally, naive T cells differentiated into Treg, which increased the secretion of IL-10 by Treg and decreased the secretion of IL-17A and IL-6 by Th17 [<xref ref-type="bibr" rid="B56">56</xref>]. Furthermore, oral administration of <italic>L. casei</italic> DN-114 001 to allergic dermatitis mice increased the number of Treg in the skin and the levels of IL-10 in LN [<xref ref-type="bibr" rid="B57">57</xref>]. Salehipour et al. found that the number of Treg was increased in MLN and the spleen, whereas serum histamine decreased but IL-10 increased after feeding <italic>B. lactis</italic>, <italic>L. casei</italic>, <italic>L. rhamnosus</italic>, <italic>L. plantarum</italic>, and sodium butyrate to mice allergic to whey protein [<xref ref-type="bibr" rid="B30">30</xref>]. In the study by Zhang et al., oral administration of <italic>C. butyricum</italic> CGMCC0313-1 increased the number of Treg and decreased the serum IL-4, IL-5, IL-13, and IL-17 levels in mice with an intestinal allergy induced by lactoglobulin [<xref ref-type="bibr" rid="B58">58</xref>].</p>
</sec>
<sec id="sec4.2.3">
<title>4.2.3. Other Aspects of Negative Immune Regulation</title>
<p>In the study by Laskowska et al., feeding bokashi preparations (a mixture of 11 probiotics) to pregnant sows increased serum IL-10 as well as IL-10 and TGF-<italic>β</italic> in the colostrum [<xref ref-type="bibr" rid="B59">59</xref>]. Moreover, in some experiments, probiotics also regulate autoimmune diseases. For example, in systemic lupus erythematosus (SLE) mice induced by pristane, feeding <italic>L. rhamnosus</italic> and <italic>Lactobacillus delbrueckii</italic> (<italic>L. delbrueckii</italic>) reduced the expression of ROR<italic>γ</italic> mRNA, downregulated Th1 and Th17 cells, and decreased the levels of IFN-<italic>γ</italic> and IL-17 [<xref ref-type="bibr" rid="B60">60</xref>].</p>
</sec>
<sec id="sec4.2.4">
<title>4.2.4. Positive Immune Regulation</title>
<p>When probiotics promote the differentiation of Th0 cells into Th17 cells or inhibit the differentiation of Th0 cells into Treg, they can positively regulate the host immune system. Tan et al. found that feeding <italic>Bifidobacterium adolescentis</italic> (<italic>B. adolescentis</italic>) could increase the number of Th17 in the gut [<xref ref-type="bibr" rid="B61">61</xref>]. Xie et al. found that by oral administration of <italic>L. plantarum</italic> NCU116 to immune suppressive mice induced by high-dose cyclophosphamide, the expression of TLR-2 and TLR-6 mRNA increased in the small intestine, which resulted in an increase of Th17 cells and the IL-17, IL-21, IL-23, and TGF-<italic>β</italic>3 levels [<xref ref-type="bibr" rid="B62">62</xref>].</p>
</sec>
</sec>
<sec id="sec4.3">
<title>4.3. B Cells</title>
<p>B cells can differentiate into plasma cells or regulatory B cells (Breg). Plasma cells can synthesize and secrete antibodies and are mainly involved in humoral immunity. Breg can perform immunological negative regulation by producing IL-10 or TGF-<italic>β</italic>. When probiotics promote the differentiation of B cells into plasma cells, positive regulation of the immune system can be achieved. When probiotics promote the differentiation of B cells into Breg, they can negatively regulate the immune system. Shi et al. fed <italic>C. butyricum</italic> to OVA-allergic mice and found an increasing number of IL-10-producing OVA-specific B cells (OVAsBC). Furthermore, they cocultured OVAsBC, OVA, and <italic>C. butyricum</italic> and showed that OVAsBC differentiated towards Breg and the secretion of IL-10 increased [<xref ref-type="bibr" rid="B63">63</xref>]. In addition, studies have shown that <italic>Lactobacillus helveticus</italic> (<italic>L. helveticus</italic>) SBT2171 stimulated B cells isolated from mouse spleens, which could inhibit lymphocyte proliferation by inhibiting the JNK signaling pathway [<xref ref-type="bibr" rid="B64">64</xref>]. In addition, Sakai et al. showed that after oral application of <italic>Lactobacillus gasseri (L. gasseri)</italic> SBT2055, B cells could produce more IgA in Peyer's patch and small intestines of mice [<xref ref-type="bibr" rid="B65">65</xref>]. Through oral administration of VSL#3 (a mixture of multiple probiotics) to macaques, Manuzak et al. discovered that B cells could secrete more IgA in the colon and LN [<xref ref-type="bibr" rid="B66">66</xref>].</p>
</sec>
<sec id="sec4.4">
<title>4.4. Dendritic Cells</title>
<p>DC is a type of professional antigen-presenting cell (APC) that can efficiently ingest, process, and present antigens. DC eventually presents antigens to T cells to affect the differentiation of T cells. Negative immune regulation can be performed when probiotics that affect DC present antigens or differentiate to DCreg.</p>
<sec id="sec4.4.1">
<title>4.4.1. Anti-inflammatory Effects</title>
<p>Mariman et al. showed that DC secreted high levels of IL-12p70, IL-23, and IL-10 after VSL#3 stimulated mouse bone marrow DC (BMDC) [<xref ref-type="bibr" rid="B67">67</xref>]. Moreover, the activation of TLR-2 receptors in DC caused the polarization of Th0 cells into Treg and high levels of IL-10 and TGF-<italic>β</italic> secretion in MLN after coculturing BMDC with probiotics [<xref ref-type="bibr" rid="B68">68</xref>]. Further evidence suggested that coculturing human peripheral blood mononuclear cells (PBMCs) with <italic>Lactobacillus crispatus (L. crispatus)</italic> SJ-3C-US increased the maturation of DC, the number of Treg, and the secretion of IL-10 [<xref ref-type="bibr" rid="B69">69</xref>].</p>
</sec>
<sec id="sec4.4.2">
<title>4.4.2. Antiallergic Effects</title>
<p>In in vivo experiments, after feeding <italic>B. infantis</italic> to mice allergic to tropomyosin, Fu et al. also found that the maturation of DC and number of CD103+ DCreg cells increased, which promoted the expression of IL-10, TGF-<italic>β</italic>, and Foxp3 mRNA in Treg [<xref ref-type="bibr" rid="B70">70</xref>]. Some studies have shown that feeding <italic>L. paracasei</italic> L9 reduced the maturation of DC and increased the expression of CD103 and number of Treg in the MLN, Peyer's patch, and spleen of mice allergic to <italic>β</italic>-lactoglobulin [<xref ref-type="bibr" rid="B71">71</xref>]. In their in vitro experiments, Adam et al. extracted BMDC from mice allergic to house dust mites and then cocultured BMDC with the <italic>Escherichia coli</italic> Nissle 1917 strain. They found that activation of the TLR-4 pathway could promote DC differentiation. Additionally, activation of NF-<italic>κ</italic>B and mitogen-activated protein kinase (MAPK) pathways can promote DC to secret more IL-10 and IL-12 [<xref ref-type="bibr" rid="B72">72</xref>]. Some studies have also shown that after <italic>E. coli</italic> O83:K24:H31 stimulating DC from cord blood of pregnant women (CBDC), the differentiation and maturation of CBDC increased. In addition, CBDC expressed a higher level of CD83 and secreted more IL-10 [<xref ref-type="bibr" rid="B73">73</xref>].</p>
</sec>
<sec id="sec4.4.3">
<title>4.4.3. Other Aspects of Negative Immune Regulation</title>
<p>By coculturing human PBMCs with <italic>Lactobacillus reuteri (L. reuteri)</italic> DSM 17938, Haileselassie et al. found that the expression of CCR7 increased in DC. Moreover, the expression of Foxp3 and IL-10 in Treg also increased [<xref ref-type="bibr" rid="B74">74</xref>]. In addition, research showed that after <italic>Kluyveromyces marxianus</italic> (a fungus that provides beneficial effects like probiotics) stimulated PBMCs, they found DC secreted more IL-12, IL-1, IL-6, and IL-10, which promoted the polarization of naive T cells to Treg [<xref ref-type="bibr" rid="B75">75</xref>].</p>
</sec>
</sec>
<sec id="sec4.5">
<title>4.5. Natural Killer Cells</title>
<p>NK cells are involved in antitumor, antiviral, hypersensitivity, and immunoregulation activities. When probiotics promote the production of NK cells, they can positively regulate immunity. Conversely, when probiotics inhibit the number of NK cells, they negatively regulate immunity. Johansson et al. stimulated PBMCs with <italic>Staphylococcus aureus</italic> (<italic>S. aureus</italic>) and then cocultured the cells with <italic>L. rhamnosus</italic> GG and <italic>L. reuteri</italic> DSM 17938. They found that <italic>S. aureus</italic>-induced T cells and NK cells to proliferate and produce IFN-<italic>γ</italic>, but probiotics <italic>L. rhamnosus</italic> GG and <italic>L. reuteri</italic> DSM 17938 inhibited this effect [<xref ref-type="bibr" rid="B76">76</xref>]. In the study by Gong et al., the cytotoxicity of NK cells was enhanced after feeding mice <italic>Bacillus subtilis (B. subtilis)</italic> BS02 and BS04, and there were changes to CD4+ and CD8+ T cells as well as the level of IFN-<italic>γ</italic> [<xref ref-type="bibr" rid="B77">77</xref>]. Studies have shown that high expression of cytotoxic receptors and IL-22 in NK cells can be achieved by NK-92MIX cell coculturing with <italic>L. plantarum</italic> [<xref ref-type="bibr" rid="B78">78</xref>]. After oral administration of <italic>Bifidobacterium longum (B. longum)</italic> MM-2 to mice given an intranasal flu virus, Kawahara et al. found that the amounts of IL-6 and TNF-<italic>α</italic> in BALF were reduced. Additionally, the activity of NK cells in the lungs and spleen was elevated [<xref ref-type="bibr" rid="B79">79</xref>]. Some researchers used AJ2 (a mixture of 8 probiotics) to stimulate PBMCs and found that NK cells were activated, and the release of inflammatory cytokines was reduced [<xref ref-type="bibr" rid="B80">80</xref>].</p>
</sec>
<sec id="sec4.6">
<title>4.6. Other Adaptive Immune Cells</title>
<p>In addition to acting on T cell and B cells, probiotics can also work on other adaptive immune cells, including follicular helper T cells (Tfh) and <italic>γδ</italic> T cells. The main function of Tfh is to assist B cells in participating in humoral immunity. The main function of <italic>γδ</italic> T cells is in innate immunity, as they can both recognize cancer antigens and kill cancer cells. Scharek-Tedin et al. fed <italic>Bacillus cereus (B. cereus)</italic> var. toyoi to weaned piglets. As a result, they found <italic>γδ</italic> T cells were significantly reduced in the blood [<xref ref-type="bibr" rid="B81">81</xref>]. Arai et al. showed that feeding heat-killed <italic>L. paracasei</italic> MCC1849 could increase the number of Tfh in Peyer's patch of mice [<xref ref-type="bibr" rid="B82">82</xref>].</p>
</sec>
<sec id="sec4.7">
<title>4.7. Other Innate Immune Cells</title>
<p>Other innate immune cells, including macrophages, neutrophils, and mast cells, could also be influenced by probiotics. Macrophages are a type of phagocytic cell whose main function is to phagocytose pathogens and activate immune cells to respond to pathogens. Neutrophils can perform chemotaxis, phagocytosis, and bactericidal actions and defense. Mast cells can secrete a variety of cytokines and participate in immune regulation. Mast cells can also release allergic mediators to mediate allergic reactions. Through in vivo experiments, Juan et al. showed that after feeding <italic>C. butyricum</italic> CGMCC0313-1 to OVA-allergic mice, the degranulation of mucosal mast cells was inhibited and the infiltration of lung inflammatory cells was also reduced. In BALF, MMP-9 was reduced and IL-10 was increased [<xref ref-type="bibr" rid="B83">83</xref>]. In addition, Kim et al. fed <italic>L. acidophilus</italic> to colitis mice and found that M2 macrophages increased in the peritoneal cavity [<xref ref-type="bibr" rid="B49">49</xref>]. Through in vitro experiments, some researchers found that coculturing mice bone marrow-derived neutrophils with <italic>L. rhamnosus</italic> GG could inhibit the phagocytic ability and the cytotoxicity of neutrophils [<xref ref-type="bibr" rid="B84">84</xref>]. Carasi et al. cocultured human PBMCs with <italic>Enterococcus durans (E. durans)</italic> (EP-1) and found that IL-6 secretion was significantly reduced, while IL-10 secretion increased. After feeding mice EP-1, they found that the expression levels of IL-17, IL-6, IL-1, IFN-<italic>γ</italic>, and CXCL1 were remarkably reduced in Peyer's patch [<xref ref-type="bibr" rid="B85">85</xref>]. Studies by Gong et al. showed that feeding mice with <italic>B. subtilis</italic> BS02 and BS04 could enhance the phagocytosis of monocytes in mice [<xref ref-type="bibr" rid="B77">77</xref>].</p>
</sec>
<sec id="sec4.8">
<title>4.8. Immunomodulatory Effects of Probiotic Fungi</title>
<p>In addition to probiotic bacteria, some fungi also have immunomodulatory effects, which can improve the host microecological balance and regulate the host immune system. Smith et al. cultured <italic>K. marxianus</italic> and <italic>S. boulardii</italic> with DCs, respectively, they found that DCs secreted increased levels of IL-12, IL-1<italic>β</italic>, IL-6, and IL-10. Besides, they found that the use of these two fungi cell wall extracts, <italic>β</italic>-glucan, could stimulate DC receptor Dectin-1, allowing DCs to secrete IL-1<italic>β</italic>, IL-6, and IL-10, but not including IL-12. Finally, they cultured <italic>K. marxianus</italic> and <italic>S. boulardii</italic> with the DC-naive T cell cocultured system; they found that <italic>K. marxianus</italic> induced the differentiation of naive T cells to Foxp3+ Treg, increased secretion of IL-10, and controlled inflammation. Moreover, <italic>S. boulardii</italic> could induce differentiation of naive T cells to Th1, resulting in an increased secretion of IFN-<italic>γ</italic> [<xref ref-type="bibr" rid="B75">75</xref>]. Thomas et al. cocultured bone marrow-derived DCs from Crohn's disease (CD) and ulcerative colitis (UC) patients with <italic>S. boulardii</italic>; they found that DCs secreted less TNF-<italic>α</italic> but more IL-6 and IL-8 [<xref ref-type="bibr" rid="B86">86</xref>]. Interestingly, the same research team cocultured <italic>S. boulardii</italic> with DCs isolated from PBMCs; they found that DCs secreted less TNF-<italic>α</italic> and IL-6 but more IL-10, thereby inhibiting T cell proliferation [<xref ref-type="bibr" rid="B87">87</xref>]. By coculturing DCs with <italic>S. boulardii</italic> and <italic>K. marxianus</italic> CBS1553, respectively, Smith et al. found that both <italic>S. boulardii</italic> and <italic>K. marxianus</italic> CBS1553 can promote IL-12, IL-10, IL-6, TNF-<italic>α</italic>, and IL-1<italic>β</italic> secretion [<xref ref-type="bibr" rid="B88">88</xref>]. In addition, by, respectively, coculturing mouse bone marrow-derived DCs and spleen cells with <italic>β</italic>-glucan extracted from the cell wall of <italic>Saccharomyces cerevisiae</italic> (<italic>S. cerevisiae</italic>), Karumuthil-Melethil et al. found that DCs and spleen cells could secrete increased IL-10, TGF-<italic>β</italic>1, and IL-2 [<xref ref-type="bibr" rid="B89">89</xref>].</p>
<p>Xu et al. firstly stimulated mouse macrophages with LPS, and then added <italic>S. cerevisiae</italic>, and found that <italic>S. cerevisiae</italic> inhibited the production of IL-1<italic>α</italic>, IL-1ra, and IL-27 by macrophages, of which mechanism may be related to the inactivation of the mitogen-activated protein kinase and TLR2 pathway in macrophages [<xref ref-type="bibr" rid="B90">90</xref>]. In addition, by feeding <italic>S. cerevisiae</italic> IFST062013 to mice, Fakruddin et al. found that high doses of <italic>S. cerevisiae</italic> IFST062013 increased the expression of TLR-2 and IFN-<italic>γ</italic> genes in the intestinal mucosa of mice, while Foxp3, TGF-<italic>β</italic>, and IL-4 gene expression decreased. They also found an increase in IL-10 in mouse serum [<xref ref-type="bibr" rid="B91">91</xref>]. Maccaferri et al. cocultured <italic>K. marxianus</italic> B0399 with PBMCs and found more IL-1<italic>β</italic>, IL-6, MIP-1<italic>α</italic>, and TNF-<italic>α</italic> released. In another experiment, they used LPS to stimulate PBMCs with <italic>K. marxianus</italic> B0399 and found the ability of LPS to trigger an inflammatory response was attenuated by <italic>K. marxianus</italic> B0399. Besides, <italic>K. marxianus</italic> B0399 can significantly reduce the concentration of proinflammatory cytokines TNF-<italic>α</italic>, IL-6, and MIP-1<italic>α</italic> secreted by PBMCs; however, IL-1<italic>β</italic> was increased [<xref ref-type="bibr" rid="B92">92</xref>]. By giving oral administration of <italic>Scytalidium acidophilum</italic> (<italic>S. acidophilum</italic>) to broilers chickens, Huang et al. found an increase in serum IgA [<xref ref-type="bibr" rid="B93">93</xref>]. Interestingly, after mice were infected with <italic>C. difficile</italic>, the mice that continued to be infected with <italic>Candida albicans</italic> (<italic>C. albicans</italic>) expressed higher levels of IL-17A in infected tissues than the mice that were not continued to be infected with <italic>C. albicans</italic>. This improves the survival rate after <italic>C. difficile</italic> infection. <italic>C. albicans</italic> may be a potential probiotic [<xref ref-type="bibr" rid="B94">94</xref>].</p>
<p>By feeding mice with Tibetan mushroom (a drink which was produced by fermentation of more than a dozen bacteria and yeasts), Diniz et al. found that the granuloma induced by cotton balls was significantly inhibited. Meanwhile, using carrageenan, dextran, and histamine to stimulate rats to get paw edema was also significantly reduced. But the experiment did not show which kind of bacteria or fungi was responsible for the anti-inflammatory function [<xref ref-type="bibr" rid="B95">95</xref>]. Zhang et al. fed mice which were allergic to peanut with ImmuBalance (a fermented soy product from <italic>Aspergillus</italic> and lactic acid); the results showed histamine and IgE levels were decreased in mice sera. Additionally, the amount of IL-4, IL-5, and IL-13 in mouse spleen cells was significantly reduced [<xref ref-type="bibr" rid="B96">96</xref>].</p>
</sec>
</sec>
<sec id="sec5">
<title>5. Efficacy and Safety of Probiotics and FMT in Clinical Trials and Application</title>
<sec id="sec5.1">
<title>5.1. Efficacy and Safety of Probiotics</title>
<p>To be effective at their likely sites of action, probiotics need to be able to survive stomach acid, bile, and digestive enzymes and to be viable for the duration of their shelf lives. Many products (e.g., yogurt) on supermarket shelves do not meet even these most basic standards [<xref ref-type="bibr" rid="B97">97</xref>]. To date, clinical trials have not been performed to test whether probiotics taken orally lose their efficacy over time. Additionally, probiotics are generally regarded as safe, but there may still be risks in certain disease populations [<xref ref-type="bibr" rid="B98">98</xref>]. To ensure patient safety, the participating patients were provided information both orally and in writing and were instructed to follow all instructions and attend clinical follow-ups with their usual gastroenterologist.</p>
<p>As described above, some probiotics have been shown to have anti-inflammatory effects and promote maintenance of the gut intestinal barrier in vitro and in murine models of IBD. This outcome may give credence to their use as a treatment option in human IBD. The results of clinical trials have been mixed, with some studies showing an improvement in the maintenance of remission or induction of remission with probiotics, while other trials have failed to show any benefit (summarized in <xref ref-type="table" rid="tab2">Table 2</xref>). In a randomized controlled trial (RCT) designed by Krag et al., supplementation with profermin (contained <italic>L. plantarum</italic> 299v) was found to be safe and well-tolerated and to definitely reduce the simple clinical colitis activity index (SCCAI) scores at a statistically and clinically significant level in patients with mild-to-moderate ulcerative colitis (UC) with a flare-up [<xref ref-type="bibr" rid="B99">99</xref>]. Fedorak et al. found early treatment (at day 90 after ileocolonic resection and reanastomosis) with VSL#3 had a larger impact on the prevention of Crohn's disease (CD) recurrence than late treatment (from days 90 to 365) [<xref ref-type="bibr" rid="B100">100</xref>]. Yoshimatsu et al. conducted a single-center RCT and found that probiotic (a bio-three tablet, containing <italic>Streptococcus faecalis</italic> (<italic>S. faecalis</italic>) T-110, <italic>C. butyricum</italic> TO-A, and <italic>Bacillus mesentericus</italic> (<italic>B. mesentericus</italic>) TO-A) therapy was useful for preventing relapses of inactive UC in patients who were already in remission [<xref ref-type="bibr" rid="B101">101</xref>]. In a multiple-center study, Tamaki et al. found that supplementation with <italic>B. longum</italic> 536 (BB536) was well-tolerated and reduced the UC disease activity index (UCDAI) scores, Rachmilewitz endoscopic index (EI), and Mayo subscores after 8 weeks in Japanese patients with mild to moderately active UC [<xref ref-type="bibr" rid="B102">102</xref>]. By contrast, Ahmed et al. designed a prospective randomized crossover study. They found that there was no difference in the colonic microflora between patients with CD or UC and that the spectrum of the gut microflora was not altered by oral synbiotic administration, which contained 4 strains of probiotics, <italic>L. acidophilus</italic> LA-5, <italic>L. delbrueckii</italic> subsp. bulgaricus LBY-27, <italic>B. animalis</italic> subsp. lactis BB-12, and <italic>S. thermophilus</italic> STY-31 [<xref ref-type="bibr" rid="B103">103</xref>]. In another prospective study, Bourreille et al. showed that although the probiotic yeast <italic>S. boulardii</italic> was safe and well tolerated, it did not appear to have any beneficial effects for patients with CD in remission after steroid or salicylate therapies [<xref ref-type="bibr" rid="B104">104</xref>]. Some clinical trials also proved that probiotics could not be used as the main treatment method for IBD. Petersen et al. used probiotics <italic>E. coli</italic> Nissle together to treat acute UC after the antibiotic ciprofloxacin. They found that there was no benefit in the use of <italic>E. coli</italic> Nissle as an add-on treatment to conventional therapies for active UC. Furthermore, treatment with <italic>E. coli</italic> Nissle without a previous antibiotic cure resulted in fewer patients reaching clinical remission [<xref ref-type="bibr" rid="B105">105</xref>]. Recently, a meta-analysis showed VSL#3 could be effective for inducing remission in active UC. Probiotics may be as effective as 5-aminosalicylates (5-ASAs) in preventing relapse of quiescent UC. The efficacy of probiotics in CD remains uncertain, and more evidence from RCTs is required before their utility is known [<xref ref-type="bibr" rid="B106">106</xref>].</p>
<p>In clinical trials of other inflammatory and immune diseases, probiotics also showed an immunomodulatory effect. Sindhu et al. provided 124 children with gastroenteritis <italic>L. rhamnosus</italic> GG (LGG) ATCC 53103 or placebo, and they found that LGG had a positive immunomodulatory effect for improving intestinal function in children with rotavirus and cryptosporidial gastroenteritis [<xref ref-type="bibr" rid="B107">107</xref>]. Maldonado-Lobón et al. carried out a 3-year study to show that early administration of the probiotic of <italic>Lactobacillus fermentum</italic> (<italic>L. fermentum</italic>) CECT5716 in an infant formula was safe, and differences were observed on the incidence of infectious and noninfectious diseases or disorders related to intestinal function [<xref ref-type="bibr" rid="B108">108</xref>]. In recurrent aphthous stomatitis (RAS), Mimura et al. found that a symbiotic treatment based on a fructooligosaccharide, <italic>Lactobacillus</italic>, and <italic>Bifidobacterium</italic> composition produced an alteration in the Th2 serological immune profile in the direction of Th1 and improved pain symptomatology [<xref ref-type="bibr" rid="B109">109</xref>]. Savino et al. used <italic>L. reuteri</italic> to treat patients suffering from infantile colic, and they found that infants with colic treated with <italic>L. reuteri</italic> for 30 days had significantly increased forkhead box P3 (FOXP3) expression, which could produce more Treg and, ultimately, reduced fecal calprotectin [<xref ref-type="bibr" rid="B110">110</xref>]. Dennis-Wall et al. determined whether consuming <italic>L. gasseri</italic> KS-13, <italic>B. bifidum</italic> G9-1, and <italic>B. longum</italic> MM-2 would improve quality of life during allergy season by increasing the percentage of Tregs and inducing tolerance [<xref ref-type="bibr" rid="B111">111</xref>]. Kim et al. identified a population of atopic dermatitis (AD) patients with a good clinical response to probiotic treatment. All patients were given <italic>L. plantarum</italic> CJLP133 once a day for 12 weeks. Their results suggested that a subgroup of patients with a specific AD phenotype showing an immunologically active state (high total IgE, increased expression of TGF-<italic>β</italic>, and high numbers of Treg) might benefit from probiotic treatment [<xref ref-type="bibr" rid="B112">112</xref>]. Sheikhi et al. also investigated immune state changes with probiotics in AD. They found that <italic>L. delbrueckii</italic> subsp. bulgaricus could modulate the secretion of Th1- and Th2-Treg-related cytokines in AD patients [<xref ref-type="bibr" rid="B113">113</xref>]. In addition to Th1- and Th2-Treg-related cytokines, Rø et al. found that perinatal maternal probiotic supplementation with a combination of LGG, <italic>B. animalis</italic> subsp. lactis Bb-12 (Bb-12), and <italic>L. acidophilus</italic> La-5 (La-5) reduced the proportion of Th22 cells in 3-month-old children with AD [<xref ref-type="bibr" rid="B114">114</xref>]. Another study showed that only probiotics had an effect on Th17, but no effect on the relative frequencies of Th1, Th2, and Treg cells among circulating PBMCs; on plasma cytokine levels; and on in vitro production of cytokines by T cells [<xref ref-type="bibr" rid="B115">115</xref>]. In addition to T cells, probiotics also could affect NK cells. Lee et al. found that daily consumption of dairy yogurt containing <italic>L. paracasei</italic> ssp. paracasei, B. lactis, and heat-treated L. plantarum could be an effective option to improve immune function by enhancing NK cell function and IFN-<italic>γ</italic> concentration [<xref ref-type="bibr" rid="B116">116</xref>]. In enthesitis-related-arthritis category of juvenile idiopathic arthritis (JIA-ERA), probiotic VSL3# capsules were well-tolerated but failed to show any significant immune (frequencies of Th1, Th2, Th17, and Treg cells in blood, serum cytokines IFN-<italic>γ</italic>, IL-4, IL-17, IL-10, TNF-<italic>α</italic>, and IL-6) or clinical effects [<xref ref-type="bibr" rid="B117">117</xref>]. Another study investigating immune responses among sedentary young males showed the total leukocytes, total lymphocytes, T lymphocytes, T-helper, T-cytotoxic, B lymphocytes, and NK cell counts in peripheral blood were not significantly affected by the probiotics [<xref ref-type="bibr" rid="B118">118</xref>]. Komano et al. found that heat-killed <italic>Lactococcus lactis</italic> (<italic>L. lactis</italic>) JCM 5805 (LC-Plasma) supplementation relieved morbidity and symptoms of URTI via activation of plasmacytoid DC (pDC) and decreased fatigue accumulation during consecutive high-intensity exercise in athletes [<xref ref-type="bibr" rid="B119">119</xref>].</p>
<p>As described above, the effects of probiotic treatment in human studies are often variable, and there are inconsistencies between different clinical trials, undoubtedly related to the fact that different multistrain probiotic combinations have been used in variable dose frequencies. It is therefore difficult to draw clinically relevant conclusions about the effects of probiotics in human studies.</p>
</sec>
<sec id="sec5.2">
<title>5.2. Efficacy and Safety of FMT</title>
<p>FMT is a complex intervention that involves multiple components, ranging from donor selection to the methods of transplantation (for example, colonoscopy) and several organizational levels, such as the use of stool banks or analysis of gut microbiota composition by a biologist [<xref ref-type="bibr" rid="B120">120</xref>]. The factors that could affect the efficacy and safety of FMT are unknown. In addition, multiple components of FMT (such as donor screening, methods for collecting stool, preparation, and transplantation) could differ among studies [<xref ref-type="bibr" rid="B121">121</xref>]. In IBD clinical trials (<xref ref-type="table" rid="tab2">Table 2</xref>), Jacob et al. carried out a single FMT delivery by colonoscopy for active UC using a 2-donor fecal microbiota preparation. Mucosal CD4+ T-cell analysis revealed a reduction in both Th1 and Treg post-FMT [<xref ref-type="bibr" rid="B122">122</xref>]. Goyal et al. found that a single FMT was relatively safe and could result in a short-term response in young patients with active IBD. Responders possessed increased fusobacterium prior to FMT and demonstrated more significant microbiome changes compared to nonresponders after FMT [<xref ref-type="bibr" rid="B123">123</xref>]. Karolewska-Bochenek and colleagues also proved that FMT had beneficial effects on pediatric UC and CD colitis, and FMT was well-tolerated and safe. However, they emphasized that a proper protocol of FMT administration was crucial for treatment efficacy [<xref ref-type="bibr" rid="B124">124</xref>]. In the same year, Pai and Popov summarized an optimal and detailed multiple-center RCT protocol of FMT for pediatric IBD [<xref ref-type="bibr" rid="B125">125</xref>]. For CDI patients with IBD, Meighani et al. revealed that FMT could provide a good alternative treatment option with high success rates for recurrent or refractory CDI in patients with well-controlled IBD who fail standard antimicrobial therapy [<xref ref-type="bibr" rid="B126">126</xref>]. Khanna et al. showed that CDI patients with IBD had a higher proportion of the original community after FMT and lacked improvement of their IBD symptoms and increased episodes of CDI in a long-term follow-up [<xref ref-type="bibr" rid="B127">127</xref>]. Another pilot study suggested that the microbial imbalances in CDI + UC recipients more closely resemble those of the CDI-only recipients compared to the UC-only recipients after a single FMT [<xref ref-type="bibr" rid="B128">128</xref>].</p>
<p>In an age of reductionist science and targeted therapeutic interventions, FMT seems oddly unsophisticated. However, FMT has been shown to be a highly efficacious, safe, and cost-effective therapy for immune diseases, especially IBD.</p>
</sec>
</sec>
<sec id="sec6">
<title>6. Conclusions and Future Perspectives</title>
<p>Probiotics have a large spectrum and have been used in main diseases, such as IBD, necrotizing enterocolitis (NEC), irritable bowel syndrome IBS, diarrhea, and other gastrointestinal diseases, in vivo and in vitro. Due to their ability to regulate systemic immune function, probiotics have recently attracted attention in the development of new treatments for obesity, insulin resistance syndrome, type 2 diabetes mellitus and nonalcoholic liver steatosis, hepatic encephalopathy, autism and chronic kidney disease, allergic asthma, atopic dermatitis (AD), acne, rheumatoid arthritis, prevention of dental caries, preventive treatment of an infection, and other fields. In addition, the use of probiotic strains as carriers of antigen delivery is a viable alternative strategy to overcome the shortcomings of vaccines. However, despite their active role in various tumor diseases, probiotics also have side effects associated with anticancer therapies.</p>
<p>The immunomodulation induced by probiotics is a complex interaction between different hosts and microorganisms, so the immunomodulatory characteristics of specific probiotics cannot be generalized. Presently, the composition, dosage, course of treatment, specific mechanism of action, and efficacy of probiotics used in clinical treatment have not been standardized. Overall, probiotics are generally considered safe, but there is growing evidence of widespread concern about the safety of probiotics. In 2002, a joint report by the World Health Organization and the United Nations Food and Agriculture Organization showed that probiotics can cause four side effects, namely, systemic infection, harmful metabolic activity, excessive immune stimulation, and gene transfer in susceptible individuals. Recently, two reports in September 2018 also noted the unknown aspects of the safety of probiotics at this stage and raised concerns in the scientific community about studying adverse reactions to probiotics. Zmora et al. [<xref ref-type="bibr" rid="B129">129</xref>] emphasize that the colonization of probiotics is highly personalized and that different individuals have different sensitivity to different probiotic colonization. The host microbiome influences probiotic colonization through competitive rejection of the same species and specific immune mechanisms. The intake of probiotics did not significantly affect the composition of the symbiotic community but instead stimulated the response of the host immune system. Therefore, we suggest that it is necessary to develop personalized probiotics from the perspective of the specificity of the intestinal flora and host physiology. When a clinical application of probiotics is selected, it should gradually transform from empirical treatment to evidence-based treatment, and suitable individualized treatment plans should be developed for patients using evidence-based treatments.</p>
<p>Suez et al. [<xref ref-type="bibr" rid="B130">130</xref>] reported that in mice and mixed probiotic intervention in healthy subjects and fecal bacteria autograft (aFMT) of antibiotics might improve the recovery of the intestinal flora after disturbance; the study illustrated that compared with spontaneous recovery, probiotic preparations significantly delayed the host's feces and the reconstruction of the intestinal mucosa flora and host the transcriptome of recovery. Moreover, this study showed that it is difficult to be fully recovered; this is mainly because of the soluble factors that secreted probiotic bacteria inhibition, and probiotics in the potential beneficial effects of antibiotic therapy possibly will be offset by intestinal mucosa recovery effect. It is important to note that microbiome transplantation enables rapid and nearly complete recovery of host-microbiome and transcriptome within a few days. This suggests that, compared with probiotics or prebiotics, fecal bacteria transplantation as the most direct method of intestinal flora intervention may be more effective and feasible.</p>
<p>Since 2013, when it was included in the FDA's official treatment guidelines for relapsing <italic>C. difficile</italic>, fecal transplants have seen more comprehensive development worldwide. Compared to the standard use of probiotics, FMT can be explored faster and further in this area. At present, the standardization of donor screening, microflora separation and preparation, transplantation, and other aspects involved in the FMT process has begun to take shape. Recently, a large number of studies [<xref ref-type="bibr" rid="B131">131</xref>–<xref ref-type="bibr" rid="B135">135</xref>] have proposed the step-up treatment strategy of FMT: when the single FMT and multiple FMTs (greater than or equal to 2) are not effective, FMT can be combined with conventional drug therapy (such as glucocorticoid, cyclosporine, anti-TNF-beta antibody, and whole intestinal nutrition). The efficacy of each step can be improved in the next step. This FMT stepwise treatment strategy is suitable for refractory IBD, immune-related diseases [<xref ref-type="bibr" rid="B135">135</xref>], and severe or complex CDI [<xref ref-type="bibr" rid="B131">131</xref>], especially for patients who are not responsive to conventional therapeutic drugs. At the same time, severe adverse events caused by FMT can be caused by infectious microorganisms in donor feces, which is because many infectious diseases in the donor are still difficult to be excluded. Therefore, FMT-related adverse events in specific populations should be prevented, especially those with low immunity. During FMT treatment through the digestive tract, improper fecal bacteria infusion technology and process may also lead to nausea, vomiting, aspiration, and other adverse events. In order to prevent FMT transmission diseases, strict donor screening should be carried out, and FMT treatment decisions, methods, short-term and long-term follow-up safety evaluation, and supervision will be the focus of future research.</p>
<p>To sum up, personalized probiotics intervention and standardized fecal bacteria transplantation should be challenges and prospects for future research on the intervention model of intestinal flora. Furthermore, increasing evidence shows that the microbiome has potential effects outside the intestinal tract, such as vagina and sinus tract [<xref ref-type="bibr" rid="B136">136</xref>], urethra, [<xref ref-type="bibr" rid="B137">137</xref>] and skin [<xref ref-type="bibr" rid="B138">138</xref>]. Therefore, future research should focus on a specific use of microbiome in different organs.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>This study was funded by grants of the National Natural Science Foundation of China (81700658 and 81500231), the Natural Science Foundation of Hunan Province (2016JJ4105), the New Xiangya Talent Project of the Third Xiangya Hospital of Central South University (JY201629 and JY201524), and the University Student Innovation Program of Central South University (ZY20180983 and ZY20180988).</p>
</ack>
<sec>
<title>Conflicts of Interest</title>
<p>The authors declare no conflict of interest.</p>
</sec>
<sec>
<title>Authors' Contributions</title>
<p>Wenjie Zeng and Jie Shen collected the literatures and drafted the initial manuscript. Liangxin Peng and Hongbo Xu assisted to make the figures and tables. Tao Bo and Moussa Ide Nasser revised the manuscript and edited the language. Quan Zhuang and Mingyi Zhao conceptualized and guaranteed the review. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. Wenjie Zeng and Jie Shen, these authors contributed equally to this study.</p>
</sec>
<ref-list>
<ref id="B1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Guarner</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic</article-title>
<source/>
<italic toggle="yes">Nature Reviews Gastroenterology &amp; Hepatology</italic>
<year>2014</year>
<volume>11</volume>
<issue>8</issue>
<fpage>506</fpage>
<lpage>514</lpage>
<pub-id pub-id-type="doi">10.1038/nrgastro.2014.66</pub-id>
<pub-id pub-id-type="other">2-s2.0-84905675648</pub-id>
<pub-id pub-id-type="pmid">24912386</pub-id>
</element-citation>
</ref>
<ref id="B2">
<label>2</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saavedra</surname>
<given-names>J. M.</given-names>
</name>
</person-group>
<article-title>Use of probiotics in pediatrics: rationale, mechanisms of action, and practical aspects</article-title>
<source/>
<italic toggle="yes">Nutrition in Clinical Practice</italic>
<year>2007</year>
<volume>22</volume>
<issue>3</issue>
<fpage>351</fpage>
<lpage>365</lpage>
<pub-id pub-id-type="doi">10.1177/0115426507022003351</pub-id>
<pub-id pub-id-type="other">2-s2.0-34347263800</pub-id>
<pub-id pub-id-type="pmid">17507735</pub-id>
</element-citation>
</ref>
<ref id="B3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaggia</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mattarelli</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Biavati</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Probiotics and prebiotics in animal feeding for safe food production</article-title>
<source/>
<italic toggle="yes">International Journal of Food Microbiology</italic>
<year>2010</year>
<volume>141</volume>
<fpage>S15</fpage>
<lpage>S28</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2010.02.031</pub-id>
<pub-id pub-id-type="other">2-s2.0-77955287672</pub-id>
<pub-id pub-id-type="pmid">20382438</pub-id>
</element-citation>
</ref>
<ref id="B4">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ji</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Should we standardize the 1,700-year-old fecal microbiota transplantation?</article-title>
<source/>
<italic toggle="yes">The American Journal of Gastroenterology</italic>
<year>2012</year>
<volume>107</volume>
<issue>11</issue>
<fpage>p. 1755</fpage>
<pub-id pub-id-type="doi">10.1038/ajg.2012.251</pub-id>
<pub-id pub-id-type="other">2-s2.0-84869395353</pub-id>
<pub-id pub-id-type="pmid">23160295</pub-id>
</element-citation>
</ref>
<ref id="B5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eiseman</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Silen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Bascom</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Kauvar</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis</article-title>
<source/>
<italic toggle="yes">Surgery</italic>
<year>1958</year>
<volume>44</volume>
<issue>5</issue>
<fpage>854</fpage>
<lpage>859</lpage>
<pub-id pub-id-type="pmid">13592638</pub-id>
</element-citation>
</ref>
<ref id="B6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sjolin</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Trottestam</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Aronsson</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces</article-title>
<source/>
<italic toggle="yes">The Lancet</italic>
<year>1983</year>
<volume>322</volume>
<issue>8354</issue>
<fpage>p. 845</fpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(83)90753-5</pub-id>
<pub-id pub-id-type="other">2-s2.0-0021097993</pub-id>
</element-citation>
</ref>
<ref id="B7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Gerding</surname>
<given-names>D. N.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Clinical practice guidelines for Clostridium difficile infection in adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)</article-title>
<source/>
<italic toggle="yes">Infection Control &amp; Hospital Epidemiology</italic>
<year>2010</year>
<volume>31</volume>
<issue>5</issue>
<fpage>431</fpage>
<lpage>455</lpage>
<pub-id pub-id-type="doi">10.1086/651706</pub-id>
<pub-id pub-id-type="other">2-s2.0-77951026738</pub-id>
<pub-id pub-id-type="pmid">20307191</pub-id>
</element-citation>
</ref>
<ref id="B8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>König</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Siebenhaar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Högenauer</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Consensus report: faecal microbiota transfer–clinical applications and procedures</article-title>
<source/>
<italic toggle="yes">Alimentary Pharmacology &amp; Therapeutics</italic>
<year>2017</year>
<volume>45</volume>
<issue>2</issue>
<fpage>222</fpage>
<lpage>239</lpage>
<pub-id pub-id-type="doi">10.1111/apt.13868</pub-id>
<pub-id pub-id-type="other">2-s2.0-85002170778</pub-id>
<pub-id pub-id-type="pmid">27891639</pub-id>
</element-citation>
</ref>
<ref id="B9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>H. H.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>Y. S.</given-names>
</name>
</person-group>
<article-title>Fecal microbiota transplantation: current applications, effectiveness, and future perspectives</article-title>
<source/>
<italic toggle="yes">Clinical Endoscopy</italic>
<year>2016</year>
<volume>49</volume>
<issue>3</issue>
<fpage>257</fpage>
<lpage>265</lpage>
<pub-id pub-id-type="doi">10.5946/ce.2015.117</pub-id>
<pub-id pub-id-type="other">2-s2.0-84971378706</pub-id>
<pub-id pub-id-type="pmid">26956193</pub-id>
</element-citation>
</ref>
<ref id="B10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannenas</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Papadopoulos</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Tsalie</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Assessment of dietary supplementation with probiotics on performance, intestinal morphology and microflora of chickens infected with <italic>Eimeria tenella</italic></article-title>
<source/>
<italic toggle="yes">Veterinary Parasitology</italic>
<year>2012</year>
<volume>188</volume>
<issue>1-2</issue>
<fpage>31</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="doi">10.1016/j.vetpar.2012.02.017</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863200734</pub-id>
<pub-id pub-id-type="pmid">22459110</pub-id>
</element-citation>
</ref>
<ref id="B11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lazado</surname>
<given-names>C. C.</given-names>
</name>
<name>
<surname>Caipang</surname>
<given-names>C. M. A.</given-names>
</name>
<name>
<surname>Brinchmann</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Kiron</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>In vitro adherence of two candidate probiotics from Atlantic cod and their interference with the adhesion of two pathogenic bacteria</article-title>
<source/>
<italic toggle="yes">Veterinary Microbiology</italic>
<year>2011</year>
<volume>148</volume>
<issue>2-4</issue>
<fpage>252</fpage>
<lpage>259</lpage>
<pub-id pub-id-type="doi">10.1016/j.vetmic.2010.08.024</pub-id>
<pub-id pub-id-type="other">2-s2.0-79951561938</pub-id>
<pub-id pub-id-type="pmid">20884135</pub-id>
</element-citation>
</ref>
<ref id="B12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Candela</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Perna</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Carnevali</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Interaction of probiotic <italic>Lactobacillus</italic> and <italic>Bifidobacterium</italic> strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production</article-title>
<source/>
<italic toggle="yes">International Journal of Food Microbiology</italic>
<year>2008</year>
<volume>125</volume>
<issue>3</issue>
<fpage>286</fpage>
<lpage>292</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijfoodmicro.2008.04.012</pub-id>
<pub-id pub-id-type="other">2-s2.0-47349131536</pub-id>
<pub-id pub-id-type="pmid">18524406</pub-id>
</element-citation>
</ref>
<ref id="B13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delgado</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>O'Sullivan</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mayo</surname>
<given-names>B.</given-names>
</name>
</person-group>
<article-title>Subtractive screening for probiotic properties of <italic>Lactobacillus</italic> species from the human gastrointestinal tract in the search for new probiotics</article-title>
<source/>
<italic toggle="yes">Journal of Food Science</italic>
<year>2007</year>
<volume>72</volume>
<issue>8</issue>
<fpage>M310</fpage>
<lpage>M315</lpage>
<pub-id pub-id-type="doi">10.1111/j.1750-3841.2007.00479.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-35348922453</pub-id>
<pub-id pub-id-type="pmid">17995611</pub-id>
</element-citation>
</ref>
<ref id="B14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ridwan</surname>
<given-names>B. U.</given-names>
</name>
<name>
<surname>Koning</surname>
<given-names>C. J.</given-names>
</name>
<name>
<surname>Besselink</surname>
<given-names>M. G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Antimicrobial activity of a multispecies probiotic (Ecologic 641) against pathogens isolated from infected pancreatic necrosis</article-title>
<source/>
<italic toggle="yes">Letters in Applied Microbiology</italic>
<year>2008</year>
<volume>46</volume>
<issue>1</issue>
<fpage>61</fpage>
<lpage>67</lpage>
<pub-id pub-id-type="doi">10.1111/j.1472-765X.2007.02260.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-37549014917</pub-id>
<pub-id pub-id-type="pmid">17944834</pub-id>
</element-citation>
</ref>
<ref id="B15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tejero-Sarinena</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Barlow</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Costabile</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gibson</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Rowland</surname>
<given-names>I.</given-names>
</name>
</person-group>
<article-title>In vitro evaluation of the antimicrobial activity of a range of probiotics against pathogens: evidence for the effects of organic acids</article-title>
<source/>
<italic toggle="yes">Anaerobe</italic>
<year>2012</year>
<volume>18</volume>
<issue>5</issue>
<fpage>530</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1016/j.anaerobe.2012.08.004</pub-id>
<pub-id pub-id-type="other">2-s2.0-84867330378</pub-id>
<pub-id pub-id-type="pmid">22959627</pub-id>
</element-citation>
</ref>
<ref id="B16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hummel</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Veltman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Cichon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sonnenborn</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>M. A.</given-names>
</name>
</person-group>
<article-title>Differential targeting of the E-cadherin/<italic>β</italic>-catenin complex by gram-positive probiotic lactobacilli improves epithelial barrier function</article-title>
<source/>
<italic toggle="yes">Applied and Environmental Microbiology</italic>
<year>2012</year>
<volume>78</volume>
<issue>4</issue>
<fpage>1140</fpage>
<lpage>1147</lpage>
<pub-id pub-id-type="doi">10.1128/AEM.06983-11</pub-id>
<pub-id pub-id-type="other">2-s2.0-84857082954</pub-id>
<pub-id pub-id-type="pmid">22179242</pub-id>
</element-citation>
</ref>
<ref id="B17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mennigen</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Nolte</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rijcken</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis</article-title>
<source/>
<italic toggle="yes">American Journal of Physiology-Gastrointestinal and Liver Physiology</italic>
<year>2009</year>
<volume>296</volume>
<issue>5</issue>
<fpage>G1140</fpage>
<lpage>G1149</lpage>
<pub-id pub-id-type="doi">10.1152/ajpgi.90534.2008</pub-id>
<pub-id pub-id-type="other">2-s2.0-66149090738</pub-id>
<pub-id pub-id-type="pmid">19221015</pub-id>
</element-citation>
</ref>
<ref id="B18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mack</surname>
<given-names>D. R.</given-names>
</name>
<name>
<surname>Ahrne</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hyde</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hollingsworth</surname>
<given-names>M. A.</given-names>
</name>
</person-group>
<article-title>Extracellular MUC3 mucin secretion follows adherence of <italic>Lactobacillus</italic> strains to intestinal epithelial cells in vitro</article-title>
<source/>
<italic toggle="yes">Gut</italic>
<year>2003</year>
<volume>52</volume>
<issue>6</issue>
<fpage>827</fpage>
<lpage>833</lpage>
<pub-id pub-id-type="doi">10.1136/gut.52.6.827</pub-id>
<pub-id pub-id-type="other">2-s2.0-0038237678</pub-id>
<pub-id pub-id-type="pmid">12740338</pub-id>
</element-citation>
</ref>
<ref id="B19">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Isolauri</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Sutas</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Kankaanpaa</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Arvilommi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Salminen</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Probiotics: effects on immunity</article-title>
<source/>
<italic toggle="yes">The American Journal of Clinical Nutrition</italic>
<year>2001</year>
<volume>73</volume>
<issue>2</issue>
<fpage>444S</fpage>
<lpage>450S</lpage>
<pub-id pub-id-type="doi">10.1093/ajcn/73.2.444s</pub-id>
<pub-id pub-id-type="pmid">11157355</pub-id>
</element-citation>
</ref>
<ref id="B20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dalla</surname>
<given-names>M. M. S.</given-names>
</name>
<name>
<surname>Yazdi</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Holakuyee</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>Z. M.</given-names>
</name>
<name>
<surname>Abolhassani</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mahdavi</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>
<italic>Lactobacillus casei ssp.casei</italic> induced Th1 cytokine profile and natural killer cells activity in invasive ductal carcinoma bearing mice</article-title>
<source/>
<italic toggle="yes">Iranian Journal of Allergy, Asthma, and Immunology</italic>
<year>2012</year>
<volume>11</volume>
<issue>2</issue>
<fpage>183</fpage>
<lpage>189</lpage>
</element-citation>
</ref>
<ref id="B21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perdigon</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Alvarez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rachid</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aguero</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Gobbato</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Immune system stimulation by probiotics</article-title>
<source/>
<italic toggle="yes">Journal of Dairy Science</italic>
<year>1995</year>
<volume>78</volume>
<issue>7</issue>
<fpage>1597</fpage>
<lpage>1606</lpage>
<pub-id pub-id-type="doi">10.3168/jds.S0022-0302(95)76784-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-0029337230</pub-id>
<pub-id pub-id-type="pmid">7593855</pub-id>
</element-citation>
</ref>
<ref id="B22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Toh</surname>
<given-names>Z. Q.</given-names>
</name>
<name>
<surname>Anzela</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>M. L. K.</given-names>
</name>
<name>
<surname>Licciardi</surname>
<given-names>P. V.</given-names>
</name>
</person-group>
<article-title>Probiotic therapy as a novel approach for allergic disease</article-title>
<source/>
<italic toggle="yes">Frontiers in Pharmacology</italic>
<year>2012</year>
<volume>3</volume>
<fpage>p. 171</fpage>
<pub-id pub-id-type="doi">10.3389/fphar.2012.00171</pub-id>
<pub-id pub-id-type="other">2-s2.0-84867131314</pub-id>
</element-citation>
</ref>
<ref id="B23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>W. R.</given-names>
</name>
</person-group>
<article-title>Fecal microbiota transplantation in treating <italic>Clostridium difficile</italic> infection</article-title>
<source/>
<italic toggle="yes">Journal of Digestive Diseases</italic>
<year>2014</year>
<volume>15</volume>
<issue>8</issue>
<fpage>405</fpage>
<lpage>408</lpage>
<pub-id pub-id-type="doi">10.1111/1751-2980.12160</pub-id>
<pub-id pub-id-type="other">2-s2.0-84904858663</pub-id>
<pub-id pub-id-type="pmid">24825534</pub-id>
</element-citation>
</ref>
<ref id="B24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sayin</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Wahlström</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Felin</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist</article-title>
<source/>
<italic toggle="yes">Cell Metabolism</italic>
<year>2013</year>
<volume>17</volume>
<issue>2</issue>
<fpage>225</fpage>
<lpage>235</lpage>
<pub-id pub-id-type="doi">10.1016/j.cmet.2013.01.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-84873342775</pub-id>
<pub-id pub-id-type="pmid">23395169</pub-id>
</element-citation>
</ref>
<ref id="B25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vrieze</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>van Nood</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Holleman</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome</article-title>
<source/>
<italic toggle="yes">Gastroenterology</italic>
<year>2012</year>
<volume>143</volume>
<issue>4</issue>
<fpage>913</fpage>
<lpage>916.e7</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2012.06.031</pub-id>
<pub-id pub-id-type="other">2-s2.0-84866738529</pub-id>
<pub-id pub-id-type="pmid">22728514</pub-id>
</element-citation>
</ref>
<ref id="B26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khoruts</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sadowsky</surname>
<given-names>M. J.</given-names>
</name>
</person-group>
<article-title>Understanding the mechanisms of faecal microbiota transplantation</article-title>
<source/>
<italic toggle="yes">Nature Reviews Gastroenterology &amp; Hepatology</italic>
<year>2016</year>
<volume>13</volume>
<issue>9</issue>
<fpage>508</fpage>
<lpage>516</lpage>
<pub-id pub-id-type="doi">10.1038/nrgastro.2016.98</pub-id>
<pub-id pub-id-type="other">2-s2.0-84975292883</pub-id>
<pub-id pub-id-type="pmid">27329806</pub-id>
</element-citation>
</ref>
<ref id="B27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weingarden</surname>
<given-names>A. R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bobr</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Microbiota transplantation restores normal fecal bile acid composition in recurrent <italic>Clostridium difficile</italic> infection</article-title>
<source/>
<italic toggle="yes">American Journal of Physiology-Gastrointestinal and Liver Physiology</italic>
<year>2014</year>
<volume>306</volume>
<issue>4</issue>
<fpage>G310</fpage>
<lpage>G319</lpage>
<pub-id pub-id-type="doi">10.1152/ajpgi.00282.2013</pub-id>
<pub-id pub-id-type="other">2-s2.0-84894105226</pub-id>
<pub-id pub-id-type="pmid">24284963</pub-id>
</element-citation>
</ref>
<ref id="B28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kelly</surname>
<given-names>C. R.</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kashyap</surname>
<given-names>P.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook</article-title>
<source/>
<italic toggle="yes">Gastroenterology</italic>
<year>2015</year>
<volume>149</volume>
<issue>1</issue>
<fpage>223</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="doi">10.1053/j.gastro.2015.05.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-84931295496</pub-id>
<pub-id pub-id-type="pmid">25982290</pub-id>
</element-citation>
</ref>
<ref id="B29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinn</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Aroniadis</surname>
<given-names>O. C.</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>L. J.</given-names>
</name>
</person-group>
<article-title>Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)?</article-title>
<source/>
<italic toggle="yes">Neurogastroenterology &amp; Motility</italic>
<year>2015</year>
<volume>27</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>29</lpage>
<pub-id pub-id-type="doi">10.1111/nmo.12479</pub-id>
<pub-id pub-id-type="other">2-s2.0-84920100399</pub-id>
<pub-id pub-id-type="pmid">25424663</pub-id>
</element-citation>
</ref>
<ref id="B30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salehipour</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Haghmorad</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sankian</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Bifidobacterium animalis</italic> in combination with human origin of <italic>Lactobacillus plantarum</italic> ameliorate neuroinflammation in experimental model of multiple sclerosis by altering CD4+ T cell subset balance</article-title>
<source/>
<italic toggle="yes">Biomedicine &amp; Pharmacotherapy</italic>
<year>2017</year>
<volume>95</volume>
<fpage>1535</fpage>
<lpage>1548</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopha.2017.08.117</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029690146</pub-id>
<pub-id pub-id-type="pmid">28946394</pub-id>
</element-citation>
</ref>
<ref id="B31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Bifidobacterium infantis ameliorates chemotherapy-induced intestinal mucositis via regulating T cell immunity in colorectal cancer rats</article-title>
<source/>
<italic toggle="yes">Cellular Physiology and Biochemistry</italic>
<year>2017</year>
<volume>42</volume>
<issue>6</issue>
<fpage>2330</fpage>
<lpage>2341</lpage>
<pub-id pub-id-type="doi">10.1159/000480005</pub-id>
<pub-id pub-id-type="other">2-s2.0-85028307630</pub-id>
<pub-id pub-id-type="pmid">28848081</pub-id>
</element-citation>
</ref>
<ref id="B32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martín</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Laval</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chain</surname>
<given-names>F.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Bifidobacterium animalis</italic> ssp. <italic>lactis</italic> CNCM-I2494 restores gut barrier permeability in chronically low-grade inflamed mice</article-title>
<source/>
<italic toggle="yes">Frontiers in Microbiology</italic>
<year>2016</year>
<volume>7</volume>
<fpage>p. 608</fpage>
<pub-id pub-id-type="doi">10.3389/fmicb.2016.00608</pub-id>
<pub-id pub-id-type="other">2-s2.0-84973462700</pub-id>
</element-citation>
</ref>
<ref id="B33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jia</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>L. L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Clostridium butyricum</italic> CGMCC0313.1 protects against autoimmune diabetes by modulating intestinal immune homeostasis and inducing pancreatic regulatory T cells</article-title>
<source/>
<italic toggle="yes">Frontiers in Immunology</italic>
<year>2017</year>
<volume>8</volume>
<fpage>p. 1345</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2017.01345</pub-id>
<pub-id pub-id-type="other">2-s2.0-85031756293</pub-id>
</element-citation>
</ref>
<ref id="B34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeom</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sur</surname>
<given-names>B. J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oral administration of <italic>Lactobacillus casei</italic> variety <italic>rhamnosus</italic> partially alleviates TMA-induced atopic dermatitis in mice through improving intestinal microbiota</article-title>
<source/>
<italic toggle="yes">Journal of Applied Microbiology</italic>
<year>2015</year>
<volume>119</volume>
<issue>2</issue>
<fpage>560</fpage>
<lpage>570</lpage>
<pub-id pub-id-type="doi">10.1111/jam.12844</pub-id>
<pub-id pub-id-type="other">2-s2.0-84937638506</pub-id>
<pub-id pub-id-type="pmid">25968453</pub-id>
</element-citation>
</ref>
<ref id="B35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>van Bergenhenegouwen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Overbeek</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Bifidobacterium breve</italic> attenuates murine dextran sodium sulfate-induced colitis and increases regulatory T cell responses</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2014</year>
<volume>9</volume>
<issue>5, article e95441</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0095441</pub-id>
<pub-id pub-id-type="other">2-s2.0-84900446756</pub-id>
<pub-id pub-id-type="pmid">24787575</pub-id>
</element-citation>
</ref>
<ref id="B36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Velez</surname>
<given-names>E. M. M.</given-names>
</name>
<name>
<surname>Maldonado Galdeano</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Carmuega</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Weill</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Bibas Bonet</surname>
<given-names>M. E.</given-names>
</name>
<name>
<surname>Perdigón</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Probiotic fermented milk consumption modulates the allergic process induced by ovoalbumin in mice</article-title>
<source/>
<italic toggle="yes">The British Journal of Nutrition</italic>
<year>2015</year>
<volume>114</volume>
<issue>4</issue>
<fpage>566</fpage>
<lpage>576</lpage>
<pub-id pub-id-type="doi">10.1017/S0007114515001981</pub-id>
<pub-id pub-id-type="other">2-s2.0-84939575082</pub-id>
<pub-id pub-id-type="pmid">26179751</pub-id>
</element-citation>
</ref>
<ref id="B37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saliganti</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kapila</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kapila</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Feeding probiotic <italic>Lactobacillus rhamnosus</italic> (MTCC 5897) fermented milk to suckling mothers alleviates ovalbumin-induced allergic sensitisation in mice offspring</article-title>
<source/>
<italic toggle="yes">The British Journal of Nutrition</italic>
<year>2015</year>
<volume>114</volume>
<issue>8</issue>
<fpage>1168</fpage>
<lpage>1179</lpage>
<pub-id pub-id-type="doi">10.1017/S000711451500286X</pub-id>
<pub-id pub-id-type="other">2-s2.0-84944163712</pub-id>
<pub-id pub-id-type="pmid">26330132</pub-id>
</element-citation>
</ref>
<ref id="B38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shandilya</surname>
<given-names>U. K.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kapila</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kansal</surname>
<given-names>V. K.</given-names>
</name>
</person-group>
<article-title>Probiotic Dahi containing <italic>Lactobacillus acidophilus</italic> and <italic>Bifidobacterium bifidum</italic> modulates immunoglobulin levels and cytokines expression in whey proteins sensitised mice</article-title>
<source/>
<italic toggle="yes">Journal of the Science of Food and Agriculture</italic>
<year>2016</year>
<volume>96</volume>
<issue>9</issue>
<fpage>3180</fpage>
<lpage>3187</lpage>
<pub-id pub-id-type="doi">10.1002/jsfa.7497</pub-id>
<pub-id pub-id-type="other">2-s2.0-84947968551</pub-id>
<pub-id pub-id-type="pmid">26459934</pub-id>
</element-citation>
</ref>
<ref id="B39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>I. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-inflammatory effects of a mixture of lactic acid bacteria and sodium butyrate in atopic dermatitis murine model</article-title>
<source/>
<italic toggle="yes">Journal of Medicinal Food</italic>
<year>2018</year>
<volume>21</volume>
<issue>7</issue>
<fpage>716</fpage>
<lpage>725</lpage>
<pub-id pub-id-type="doi">10.1089/jmf.2017.4116</pub-id>
<pub-id pub-id-type="other">2-s2.0-85050280454</pub-id>
<pub-id pub-id-type="pmid">29648971</pub-id>
</element-citation>
</ref>
<ref id="B40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Oh</surname>
<given-names>H. N.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>C. Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oral administration of <italic>Lactobacillus plantarum</italic> CJLP133 and CJLP243 alleviates birch pollen-induced allergic rhinitis in mice</article-title>
<source/>
<italic toggle="yes">Journal of Applied Microbiology</italic>
<year>2018</year>
<volume>124</volume>
<issue>3</issue>
<fpage>821</fpage>
<lpage>828</lpage>
<pub-id pub-id-type="doi">10.1111/jam.13635</pub-id>
<pub-id pub-id-type="other">2-s2.0-85041023335</pub-id>
<pub-id pub-id-type="pmid">29130606</pub-id>
</element-citation>
</ref>
<ref id="B41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ménard</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Gafa</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Kapel</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Butel</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Waligora-Dupriet</surname>
<given-names>A. J.</given-names>
</name>
</person-group>
<article-title>Characterization of immunostimulatory CpG-rich sequences from different <italic>Bifidobacterium</italic> species</article-title>
<source/>
<italic toggle="yes">Applied and Environmental Microbiology</italic>
<year>2010</year>
<volume>76</volume>
<issue>9</issue>
<fpage>2846</fpage>
<lpage>2855</lpage>
<pub-id pub-id-type="doi">10.1128/AEM.01714-09</pub-id>
<pub-id pub-id-type="other">2-s2.0-77951569874</pub-id>
<pub-id pub-id-type="pmid">20208019</pub-id>
</element-citation>
</ref>
<ref id="B42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname>
<given-names>H. K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Amelioration of experimental autoimmune encephalomyelitis by probiotic mixture is mediated by a shift in T helper cell immune response</article-title>
<source/>
<italic toggle="yes">Clinical Immunology</italic>
<year>2013</year>
<volume>146</volume>
<issue>3</issue>
<fpage>217</fpage>
<lpage>227</lpage>
<pub-id pub-id-type="doi">10.1016/j.clim.2013.01.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-84873714598</pub-id>
<pub-id pub-id-type="pmid">23416238</pub-id>
</element-citation>
</ref>
<ref id="B43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mangalam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Shahi</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Luckey</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Human gut-derived commensal bacteria suppress CNS inflammatory and demyelinating disease</article-title>
<source/>
<italic toggle="yes">Cell Reports</italic>
<year>2017</year>
<volume>20</volume>
<issue>6</issue>
<fpage>1269</fpage>
<lpage>1277</lpage>
<pub-id pub-id-type="doi">10.1016/j.celrep.2017.07.031</pub-id>
<pub-id pub-id-type="other">2-s2.0-85026854161</pub-id>
<pub-id pub-id-type="pmid">28793252</pub-id>
</element-citation>
</ref>
<ref id="B44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haghikia</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jörg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Duscha</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Dietary fatty acids directly impact central nervous system autoimmunity via the small intestine</article-title>
<source/>
<italic toggle="yes">Immunity</italic>
<year>2015</year>
<volume>43</volume>
<issue>4</issue>
<fpage>817</fpage>
<lpage>829</lpage>
<pub-id pub-id-type="doi">10.1016/j.immuni.2015.09.007</pub-id>
<pub-id pub-id-type="other">2-s2.0-84944682179</pub-id>
<pub-id pub-id-type="pmid">26488817</pub-id>
</element-citation>
</ref>
<ref id="B45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>
<italic>Faecalibacterium prausnitzii</italic> upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis</article-title>
<source/>
<italic toggle="yes">Journal of Crohn's and Colitis</italic>
<year>2013</year>
<volume>7</volume>
<issue>11</issue>
<fpage>e558</fpage>
<lpage>e568</lpage>
<pub-id pub-id-type="doi">10.1016/j.crohns.2013.04.002</pub-id>
<pub-id pub-id-type="other">2-s2.0-84884816918</pub-id>
<pub-id pub-id-type="pmid">23643066</pub-id>
</element-citation>
</ref>
<ref id="B46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rodríguez-Nogales</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Algieri</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Garrido-Mesa</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Differential intestinal anti-inflammatory effects of <italic>Lactobacillus fermentum</italic> and <italic>Lactobacillus salivarius</italic> in DSS mouse colitis: impact on microRNAs expression and microbiota composition</article-title>
<source/>
<italic toggle="yes">Molecular Nutrition &amp; Food Research</italic>
<year>2017</year>
<volume>61</volume>
<issue>11</issue>
<pub-id pub-id-type="doi">10.1002/mnfr.201700144</pub-id>
<pub-id pub-id-type="other">2-s2.0-85032665087</pub-id>
</element-citation>
</ref>
<ref id="B47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanda</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nishida</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ohno</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Enterococcus durans</italic> TN-3 induces regulatory T cells and suppresses the development of dextran sulfate sodium (DSS)-induced experimental colitis</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2016</year>
<volume>11</volume>
<issue>7, article e0159705</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0159705</pub-id>
<pub-id pub-id-type="other">2-s2.0-84979620552</pub-id>
<pub-id pub-id-type="pmid">27438072</pub-id>
</element-citation>
</ref>
<ref id="B48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Jhun</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Lactobacillus acidophilus</italic> improves intestinal inflammation in an acute colitis mouse model by regulation of Th17 and Treg cell balance and fibrosis development</article-title>
<source/>
<italic toggle="yes">Journal of Medicinal Food</italic>
<year>2018</year>
<volume>21</volume>
<issue>3</issue>
<fpage>215</fpage>
<lpage>224</lpage>
<pub-id pub-id-type="doi">10.1089/jmf.2017.3990</pub-id>
<pub-id pub-id-type="other">2-s2.0-85044682465</pub-id>
<pub-id pub-id-type="pmid">29336663</pub-id>
</element-citation>
</ref>
<ref id="B49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Lactobacillus acidophilus</italic> suppresses intestinal inflammation by inhibiting endoplasmic reticulum stress</article-title>
<source/>
<italic toggle="yes">Journal of Gastroenterology and Hepatology</italic>
<year>2019</year>
<volume>34</volume>
<issue>1</issue>
<fpage>178</fpage>
<lpage>185</lpage>
<pub-id pub-id-type="doi">10.1111/jgh.14362</pub-id>
<pub-id pub-id-type="other">2-s2.0-85050597419</pub-id>
<pub-id pub-id-type="pmid">29933526</pub-id>
</element-citation>
</ref>
<ref id="B50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Jhun</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A combination with probiotic complex, zinc, and coenzyme Q10 attenuates autoimmune arthritis by regulation of Th17/Treg balance</article-title>
<source/>
<italic toggle="yes">Journal of Medicinal Food</italic>
<year>2018</year>
<volume>21</volume>
<issue>1</issue>
<fpage>39</fpage>
<lpage>46</lpage>
<pub-id pub-id-type="doi">10.1089/jmf.2017.3952</pub-id>
<pub-id pub-id-type="other">2-s2.0-85040914839</pub-id>
<pub-id pub-id-type="pmid">29346060</pub-id>
</element-citation>
</ref>
<ref id="B51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cortes-Perez</surname>
<given-names>N. G.</given-names>
</name>
<name>
<surname>Lozano-Ojalvo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Maiga</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Hazebrouck</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Adel-Patient</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Intragastric administration of <italic>Lactobacillus casei</italic> BL23 induces regulatory FoxP3+ROR<italic>γ</italic>t+ T cells subset in mice</article-title>
<source/>
<italic toggle="yes">Beneficial Microbes</italic>
<year>2017</year>
<volume>8</volume>
<issue>3</issue>
<fpage>433</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.3920/BM2016.0174</pub-id>
<pub-id pub-id-type="other">2-s2.0-85019668242</pub-id>
<pub-id pub-id-type="pmid">28504580</pub-id>
</element-citation>
</ref>
<ref id="B52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lim</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Weissella cibaria</italic> WIKIM28 ameliorates atopic dermatitis-like skin lesions by inducing tolerogenic dendritic cells and regulatory T cells in BALB/c mice</article-title>
<source/>
<italic toggle="yes">Scientific Reports</italic>
<year>2017</year>
<volume>7</volume>
<issue>1, article 40040</issue>
<pub-id pub-id-type="doi">10.1038/srep40040</pub-id>
<pub-id pub-id-type="other">2-s2.0-85008949774</pub-id>
<pub-id pub-id-type="pmid">28067304</pub-id>
</element-citation>
</ref>
<ref id="B53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Lactobacillus acidophilus</italic> suppresses colitis-associated activation of the IL-23/Th17 axis</article-title>
<source/>
<italic toggle="yes">Journal of Immunology Research</italic>
<year>2015</year>
<volume>2015</volume>
<fpage>10</fpage>
<pub-id pub-id-type="doi">10.1155/2015/909514</pub-id>
<pub-id pub-id-type="other">2-s2.0-84929340454</pub-id>
<pub-id pub-id-type="publisher-id">909514</pub-id>
</element-citation>
</ref>
<ref id="B54">
<label>54</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>S. J.</given-names>
</name>
</person-group>
<article-title>Effects of <italic>Lactobacillus rhamnosus</italic> on allergic march model by suppressing Th2, Th17, and TSLP responses via CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup> Tregs</article-title>
<source/>
<italic toggle="yes">Clinical Immunology</italic>
<year>2014</year>
<volume>153</volume>
<issue>1</issue>
<fpage>178</fpage>
<lpage>186</lpage>
<pub-id pub-id-type="doi">10.1016/j.clim.2014.04.008</pub-id>
<pub-id pub-id-type="other">2-s2.0-84900037102</pub-id>
<pub-id pub-id-type="pmid">24769377</pub-id>
</element-citation>
</ref>
<ref id="B55">
<label>55</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Maeyama</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Oral administration of <italic>Enterococcus faecalis</italic> FK-23 suppresses Th17 cell development and attenuates allergic airway responses in mice</article-title>
<source/>
<italic toggle="yes">International Journal of Molecular Medicine</italic>
<year>2012</year>
<volume>30</volume>
<issue>2</issue>
<fpage>248</fpage>
<lpage>254</lpage>
<pub-id pub-id-type="doi">10.3892/ijmm.2012.1010</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863542689</pub-id>
<pub-id pub-id-type="pmid">22641478</pub-id>
</element-citation>
</ref>
<ref id="B56">
<label>56</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Lactic acid bacteria-specific induction of CD4<sup>+</sup>Foxp3<sup>+</sup>T cells ameliorates shrimp tropomyosin-induced allergic response in mice via suppression of mTOR signaling</article-title>
<source/>
<italic toggle="yes">Scientific reports</italic>
<year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>p. 1987</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-02260-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-85019500728</pub-id>
<pub-id pub-id-type="pmid">28512288</pub-id>
</element-citation>
</ref>
<ref id="B57">
<label>57</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hacini-Rachinel</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Gheit</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Le Luduec</surname>
<given-names>J. B.</given-names>
</name>
<name>
<surname>Dif</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nancey</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kaiserlian</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Oral probiotic control skin inflammation by acting on both effector and regulatory T cells</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2009</year>
<volume>4</volume>
<issue>3, article e4903</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0004903</pub-id>
<pub-id pub-id-type="other">2-s2.0-63749121653</pub-id>
<pub-id pub-id-type="pmid">19300508</pub-id>
</element-citation>
</ref>
<ref id="B58">
<label>58</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oral administration of <italic>Clostridium butyricum</italic> CGMCC0313-1 inhibits <italic>β</italic>-lactoglobulin-induced intestinal anaphylaxis in a mouse model of food allergy</article-title>
<source/>
<italic toggle="yes">Gut Pathogens</italic>
<year>2017</year>
<volume>9</volume>
<issue>1</issue>
<fpage>p. 11</fpage>
<pub-id pub-id-type="doi">10.1186/s13099-017-0160-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-85013392435</pub-id>
<pub-id pub-id-type="pmid">28250847</pub-id>
</element-citation>
</ref>
<ref id="B59">
<label>59</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laskowska</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jarosz</surname>
<given-names>Ł.</given-names>
</name>
<name>
<surname>Grądzki</surname>
<given-names>Z.</given-names>
</name>
</person-group>
<article-title>Effect of multi-microbial probiotic formulation bokashi on pro- and anti-inflammatory cytokines profile in the serum, colostrum and milk of sows, and in a culture of polymorphonuclear cells isolated from colostrum</article-title>
<source/>
<italic toggle="yes">Probiotics and Antimicrobial Proteins</italic>
<year>2018</year>
<volume>11</volume>
<fpage>220</fpage>
<lpage>232</lpage>
<pub-id pub-id-type="doi">10.1007/s12602-017-9380-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-85040043844</pub-id>
</element-citation>
</ref>
<ref id="B60">
<label>60</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mardani</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Mahmoudi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Esmaeili</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Khorasani</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tabasi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Rastin</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>In vivo study: Th1-Th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic <italic>Lactobacillus</italic> probiotics</article-title>
<source/>
<italic toggle="yes">Journal of Cellular Physiology</italic>
<year>2018</year>
<volume>234</volume>
<issue>1</issue>
<fpage>642</fpage>
<lpage>649</lpage>
<pub-id pub-id-type="doi">10.1002/jcp.26819</pub-id>
<pub-id pub-id-type="other">2-s2.0-85052616843</pub-id>
<pub-id pub-id-type="pmid">30078223</pub-id>
</element-citation>
</ref>
<ref id="B61">
<label>61</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>T. G.</given-names>
</name>
<name>
<surname>Sefik</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Geva-Zatorsky</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identifying species of symbiont bacteria from the human gut that, alone, can induce intestinal Th17 cells in mice</article-title>
<source/>
<italic toggle="yes">Proceedings of the National Academy of Sciences of the United States of America</italic>
<year>2016</year>
<volume>113</volume>
<issue>50</issue>
<fpage>E8141</fpage>
<lpage>E8150</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1617460113</pub-id>
<pub-id pub-id-type="other">2-s2.0-85003426944</pub-id>
<pub-id pub-id-type="pmid">27911839</pub-id>
</element-citation>
</ref>
<ref id="B62">
<label>62</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Nie</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Lactobacillus plantarum</italic> NCU116 attenuates cyclophosphamide-induced immunosuppression and regulates Th17/Treg cell immune responses in mice</article-title>
<source/>
<italic toggle="yes">Journal of Agricultural and Food Chemistry</italic>
<year>2016</year>
<volume>64</volume>
<issue>6</issue>
<fpage>1291</fpage>
<lpage>1297</lpage>
<pub-id pub-id-type="doi">10.1021/acs.jafc.5b06177</pub-id>
<pub-id pub-id-type="other">2-s2.0-84958819028</pub-id>
<pub-id pub-id-type="pmid">26822718</pub-id>
</element-citation>
</ref>
<ref id="B63">
<label>63</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L. Z.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Specific immunotherapy in combination with <italic>Clostridium butyricum</italic> inhibits allergic inflammation in the mouse intestine</article-title>
<source/>
<italic toggle="yes">Scientific reports</italic>
<year>2016</year>
<volume>5</volume>
<issue>1</issue>
<pub-id pub-id-type="doi">10.1038/srep17651</pub-id>
<pub-id pub-id-type="other">2-s2.0-84948783347</pub-id>
</element-citation>
</ref>
<ref id="B64">
<label>64</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hosoya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Yamashita</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Lactobacillus helveticus</italic> SBT2171 inhibits lymphocyte proliferation by regulation of the JNK signaling pathway</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2014</year>
<volume>9</volume>
<issue>9, article e108360</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0108360</pub-id>
<pub-id pub-id-type="other">2-s2.0-84907486208</pub-id>
<pub-id pub-id-type="pmid">25268890</pub-id>
</element-citation>
</ref>
<ref id="B65">
<label>65</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakai</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hosoya</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ono-Ohmachi</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Lactobacillus gasseri</italic> SBT2055 induces TGF-<italic>β</italic> expression in dendritic cells and activates TLR2 signal to produce IgA in the small intestine</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2014</year>
<volume>9</volume>
<issue>8, article e105370</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0105370</pub-id>
<pub-id pub-id-type="other">2-s2.0-84922716974</pub-id>
</element-citation>
</ref>
<ref id="B66">
<label>66</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manuzak</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Hensley-McBain</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zevin</surname>
<given-names>A. S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Enhancement of microbiota in healthy macaques results in beneficial modulation of mucosal and systemic immune function</article-title>
<source/>
<italic toggle="yes">Journal of Immunology</italic>
<year>2016</year>
<volume>196</volume>
<issue>5</issue>
<fpage>2401</fpage>
<lpage>2409</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1502470</pub-id>
<pub-id pub-id-type="other">2-s2.0-84962026552</pub-id>
<pub-id pub-id-type="pmid">26826246</pub-id>
</element-citation>
</ref>
<ref id="B67">
<label>67</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mariman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Kremer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Koning</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Nagelkerken</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>The probiotic mixture VSL#3 mediates both pro- and anti-inflammatory responses in bone marrow-derived dendritic cells from C57BL/6 and BALB/c mice</article-title>
<source/>
<italic toggle="yes">The British Journal of Nutrition</italic>
<year>2014</year>
<volume>112</volume>
<issue>7</issue>
<fpage>1088</fpage>
<lpage>1097</lpage>
<pub-id pub-id-type="doi">10.1017/S000711451400169X</pub-id>
<pub-id pub-id-type="other">2-s2.0-84921763660</pub-id>
<pub-id pub-id-type="pmid">25181025</pub-id>
</element-citation>
</ref>
<ref id="B68">
<label>68</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thakur</surname>
<given-names>B. K.</given-names>
</name>
<name>
<surname>Saha</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Banik</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Live and heat-killed probiotic <italic>Lactobacillus casei</italic> Lbs2 protects from experimental colitis through Toll-like receptor 2-dependent induction of T-regulatory response</article-title>
<source/>
<italic toggle="yes">International Immunopharmacology</italic>
<year>2016</year>
<volume>36</volume>
<fpage>39</fpage>
<lpage>50</lpage>
<pub-id pub-id-type="doi">10.1016/j.intimp.2016.03.033</pub-id>
<pub-id pub-id-type="other">2-s2.0-84964339327</pub-id>
<pub-id pub-id-type="pmid">27107798</pub-id>
</element-citation>
</ref>
<ref id="B69">
<label>69</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eslami</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hadjati</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Motevaseli</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Lactobacillus crispatus</italic> strain SJ-3C-US induces human dendritic cells (DCs) maturation and confers an anti-inflammatory phenotype to DCs</article-title>
<source/>
<italic toggle="yes">APMIS</italic>
<year>2016</year>
<volume>124</volume>
<issue>8</issue>
<fpage>697</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="doi">10.1111/apm.12556</pub-id>
<pub-id pub-id-type="other">2-s2.0-84978914848</pub-id>
<pub-id pub-id-type="pmid">27245496</pub-id>
</element-citation>
</ref>
<ref id="B70">
<label>70</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>
<italic>Bifidobacterium infantis</italic> potentially alleviates shrimp tropomyosin-induced allergy by tolerogenic dendritic cell-dependent induction of regulatory T cells and alterations in gut microbiota</article-title>
<source/>
<italic toggle="yes">Frontiers in Immunology</italic>
<year>2017</year>
<volume>8</volume>
<pub-id pub-id-type="doi">10.3389/fimmu.2017.01536</pub-id>
<pub-id pub-id-type="other">2-s2.0-85034056685</pub-id>
</element-citation>
</ref>
<ref id="B71">
<label>71</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Induction of regulatory dendritic cells by <italic>Lactobacillus paracasei</italic> L9 prevents allergic sensitization to bovine <italic>β</italic>-lactoglobulin in mice</article-title>
<source/>
<italic toggle="yes">Journal of Microbiology and Biotechnology</italic>
<year>2015</year>
<volume>25</volume>
<issue>10</issue>
<fpage>1687</fpage>
<lpage>1696</lpage>
<pub-id pub-id-type="doi">10.4014/jmb.1503.03022</pub-id>
<pub-id pub-id-type="other">2-s2.0-84945303360</pub-id>
<pub-id pub-id-type="pmid">26095382</pub-id>
</element-citation>
</ref>
<ref id="B72">
<label>72</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adam</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Delbrassinne</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bouillot</surname>
<given-names>C.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Probiotic <italic>Escherichia coli</italic> Nissle 1917 activates DC and prevents house dust mite allergy through a TLR4-dependent pathway</article-title>
<source/>
<italic toggle="yes">European Journal of Immunology</italic>
<year>2010</year>
<volume>40</volume>
<issue>7</issue>
<fpage>1995</fpage>
<lpage>2005</lpage>
<pub-id pub-id-type="doi">10.1002/eji.200939913</pub-id>
<pub-id pub-id-type="other">2-s2.0-77954138397</pub-id>
<pub-id pub-id-type="pmid">20432233</pub-id>
</element-citation>
</ref>
<ref id="B73">
<label>73</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Súkeníková</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Černý</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Novotná</surname>
<given-names>O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Different capacity of in vitro generated myeloid dendritic cells of newborns of healthy and allergic mothers to respond to probiotic strain E. coli O83:K24:H31</article-title>
<source/>
<italic toggle="yes">Immunology Letters</italic>
<year>2017</year>
<volume>189</volume>
<fpage>82</fpage>
<lpage>89</lpage>
<pub-id pub-id-type="doi">10.1016/j.imlet.2017.05.013</pub-id>
<pub-id pub-id-type="other">2-s2.0-85020034790</pub-id>
<pub-id pub-id-type="pmid">28554713</pub-id>
</element-citation>
</ref>
<ref id="B74">
<label>74</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haileselassie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Navis</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Vu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Qazi</surname>
<given-names>K. R.</given-names>
</name>
<name>
<surname>Rethi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sverremark-Ekström</surname>
<given-names>E.</given-names>
</name>
</person-group>
<article-title>Postbiotic modulation of retinoic acid imprinted mucosal-like dendritic cells by probiotic <italic>Lactobacillus reuteri</italic> 17938 in vitro</article-title>
<source/>
<italic toggle="yes">Frontiers in Immunology</italic>
<year>2016</year>
<volume>7</volume>
<fpage>p. 96</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2016.00096</pub-id>
<pub-id pub-id-type="other">2-s2.0-84964680370</pub-id>
</element-citation>
</ref>
<ref id="B75">
<label>75</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>J. E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Kluyveromyces marxianus</italic> and <italic>Saccharomyces boulardii</italic> induce distinct levels of dendritic cell cytokine secretion and significantly different T cell responses <italic>in vitro</italic></article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2016</year>
<volume>11</volume>
<issue>11, article e0167410</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0167410</pub-id>
<pub-id pub-id-type="other">2-s2.0-85002641948</pub-id>
<pub-id pub-id-type="pmid">27898740</pub-id>
</element-citation>
</ref>
<ref id="B76">
<label>76</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johansson</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Björkander</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mata Forsberg</surname>
<given-names>M.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Probiotic lactobacilli modulate <italic>Staphylococcus aureus</italic>-induced activation of conventional and unconventional T cells and NK cells</article-title>
<source/>
<italic toggle="yes">Frontiers in Immunology</italic>
<year>2016</year>
<volume>7</volume>
<fpage>p. 273</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2016.00273</pub-id>
<pub-id pub-id-type="other">2-s2.0-84983268805</pub-id>
</element-citation>
</ref>
<ref id="B77">
<label>77</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Spores of two probiotic <italic>Bacillus</italic> species enhance cellular immunity in BALB/C mice</article-title>
<source/>
<italic toggle="yes">Canadian Journal of Microbiology</italic>
<year>2018</year>
<volume>64</volume>
<issue>1</issue>
<fpage>41</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1139/cjm-2017-0373</pub-id>
<pub-id pub-id-type="other">2-s2.0-85040033271</pub-id>
<pub-id pub-id-type="pmid">29078062</pub-id>
</element-citation>
</ref>
<ref id="B78">
<label>78</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>
<italic>Lactobacillus plantarum</italic> enhanced IL-22 production in natural killer (NK) cells that protect the integrity of intestinal epithelial cell barrier damaged by enterotoxigenic <italic>Escherichia coli</italic></article-title>
<source/>
<italic toggle="yes">International Journal of Molecular Sciences</italic>
<year>2017</year>
<volume>18</volume>
<issue>11</issue>
<pub-id pub-id-type="doi">10.3390/ijms18112409</pub-id>
<pub-id pub-id-type="other">2-s2.0-85034445072</pub-id>
<pub-id pub-id-type="pmid">29137183</pub-id>
</element-citation>
</ref>
<ref id="B79">
<label>79</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kawahara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Oishi</surname>
<given-names>K.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Consecutive oral administration of <italic>Bifidobacterium longum</italic> MM-2 improves the defense system against influenza virus infection by enhancing natural killer cell activity in a murine model</article-title>
<source/>
<italic toggle="yes">Microbiology and Immunology</italic>
<year>2015</year>
<volume>59</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="doi">10.1111/1348-0421.12210</pub-id>
<pub-id pub-id-type="other">2-s2.0-84927741155</pub-id>
<pub-id pub-id-type="pmid">25400245</pub-id>
</element-citation>
</ref>
<ref id="B80">
<label>80</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bui</surname>
<given-names>V. T.</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Kozlowska</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Augmented IFN-<italic>γ</italic> and TNF-<italic>α</italic> induced by probiotic bacteria in NK cells mediate differentiation of stem-like tumors leading to inhibition of tumor growth and reduction in inflammatory cytokine release; regulation by IL-10</article-title>
<source/>
<italic toggle="yes">Frontiers in Immunology</italic>
<year>2015</year>
<volume>6</volume>
<fpage>p. 576</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2015.00576</pub-id>
<pub-id pub-id-type="other">2-s2.0-84954205996</pub-id>
</element-citation>
</ref>
<ref id="B81">
<label>81</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scharek-Tedin</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Pieper</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Vahjen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Tedin</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Neumann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zentek</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>
<italic>Bacillus cereus</italic> var. Toyoi modulates the immune reaction and reduces the occurrence of diarrhea in piglets challenged with <italic>Salmonella</italic> typhimurium DT104</article-title>
<source/>
<italic toggle="yes">Journal of Animal Science</italic>
<year>2013</year>
<volume>91</volume>
<issue>12</issue>
<fpage>5696</fpage>
<lpage>5704</lpage>
<pub-id pub-id-type="doi">10.2527/jas.2013-6382</pub-id>
<pub-id pub-id-type="other">2-s2.0-85018040765</pub-id>
<pub-id pub-id-type="pmid">24126275</pub-id>
</element-citation>
</ref>
<ref id="B82">
<label>82</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iwabuchi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>J. Z.</given-names>
</name>
<name>
<surname>Abe</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hachimura</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Orally administered heat-killed <italic>Lactobacillus paracasei</italic> MCC1849 enhances antigen-specific IgA secretion and induces follicular helper T cells in mice</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2018</year>
<volume>13</volume>
<issue>6, article e0199018</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0199018</pub-id>
<pub-id pub-id-type="other">2-s2.0-85048991498</pub-id>
<pub-id pub-id-type="pmid">29897995</pub-id>
</element-citation>
</ref>
<ref id="B83">
<label>83</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Juan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao-Ling</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ming-Hua</surname>
<given-names>Z.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oral administration of <italic>Clostridium butyricum</italic> CGMCC0313-1 reduces ovalbumin-induced allergic airway inflammation in mice</article-title>
<source/>
<italic toggle="yes">Respirology</italic>
<year>2017</year>
<volume>22</volume>
<issue>5</issue>
<fpage>898</fpage>
<lpage>904</lpage>
<pub-id pub-id-type="doi">10.1111/resp.12985</pub-id>
<pub-id pub-id-type="other">2-s2.0-85020246035</pub-id>
<pub-id pub-id-type="pmid">28122397</pub-id>
</element-citation>
</ref>
<ref id="B84">
<label>84</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lorentz</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Assa</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Glogauer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sherman</surname>
<given-names>P. M.</given-names>
</name>
</person-group>
<article-title>Probiotic <italic>Lactobacillus rhamnosus</italic> inhibits the formation of neutrophil extracellular traps</article-title>
<source/>
<italic toggle="yes">Journal of Immunology</italic>
<year>2014</year>
<volume>192</volume>
<issue>4</issue>
<fpage>1870</fpage>
<lpage>1877</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1302286</pub-id>
<pub-id pub-id-type="other">2-s2.0-84894266945</pub-id>
</element-citation>
</ref>
<ref id="B85">
<label>85</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carasi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Racedo</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Jacquot</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Elie</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Serradell</surname>
<given-names>M. Á.</given-names>
</name>
<name>
<surname>Urdaci</surname>
<given-names>M. C.</given-names>
</name>
</person-group>
<article-title>
<italic>Enterococcus durans</italic> EP1 a promising anti-inflammatory probiotic able to stimulate sIgA and to increase <italic>Faecalibacterium prausnitzii</italic> abundance</article-title>
<source/>
<italic toggle="yes">Frontiers in Immunology</italic>
<year>2017</year>
<volume>8</volume>
<fpage>p. 88</fpage>
<pub-id pub-id-type="doi">10.3389/fimmu.2017.00088</pub-id>
<pub-id pub-id-type="other">2-s2.0-85014422167</pub-id>
</element-citation>
</ref>
<ref id="B86">
<label>86</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Metzke</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dorffel</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Baumgart</surname>
<given-names>D. C.</given-names>
</name>
</person-group>
<article-title>Anti-inflammatory effects of <italic>Saccharomyces boulardii</italic> mediated by myeloid dendritic cells from patients with Crohn’s disease and ulcerative colitis</article-title>
<source/>
<italic toggle="yes">American Journal of Physiology-Gastrointestinal and Liver Physiology</italic>
<year>2011</year>
<volume>301</volume>
<issue>6</issue>
<fpage>G1083</fpage>
<lpage>G1092</lpage>
<pub-id pub-id-type="doi">10.1152/ajpgi.00217.2011</pub-id>
<pub-id pub-id-type="other">2-s2.0-82455175811</pub-id>
<pub-id pub-id-type="pmid">21903765</pub-id>
</element-citation>
</ref>
<ref id="B87">
<label>87</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Przesdzing</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Metzke</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Radbruch</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Baumgart</surname>
<given-names>D. C.</given-names>
</name>
</person-group>
<article-title>
<italic>Saccharomyces boulardii</italic> inhibits lipopolysaccharide-induced activation of human dendritic cells and T cell proliferation</article-title>
<source/>
<italic toggle="yes">Clinical and Experimental Immunology</italic>
<year>2009</year>
<volume>156</volume>
<issue>1</issue>
<fpage>78</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2249.2009.03878.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-61849185743</pub-id>
<pub-id pub-id-type="pmid">19161443</pub-id>
</element-citation>
</ref>
<ref id="B88">
<label>88</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Arneborg</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Jespersen</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Yeast modulation of human dendritic cell cytokine secretion: an in vitro study</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2014</year>
<volume>9</volume>
<issue>5, article e96595</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0096595</pub-id>
<pub-id pub-id-type="other">2-s2.0-84901236147</pub-id>
<pub-id pub-id-type="pmid">24816850</pub-id>
</element-citation>
</ref>
<ref id="B89">
<label>89</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karumuthil-Melethil</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gudi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>B. M.</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Vasu</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Fungal <italic>β</italic>-glucan, a Dectin-1 ligand, promotes protection from type 1 diabetes by inducing regulatory innate immune response</article-title>
<source/>
<italic toggle="yes">Journal of Immunology</italic>
<year>2014</year>
<volume>193</volume>
<issue>7</issue>
<fpage>3308</fpage>
<lpage>3321</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.1400186</pub-id>
<pub-id pub-id-type="other">2-s2.0-84907222568</pub-id>
<pub-id pub-id-type="pmid">25143443</pub-id>
</element-citation>
</ref>
<ref id="B90">
<label>90</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yasuda</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ashida</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>
<italic>β-</italic>Glucan from <italic>Saccharomyces cerevisiae</italic> reduces lipopolysaccharide-induced inflammatory responses in RAW264.7 macrophages</article-title>
<source/>
<italic toggle="yes">Biochimica et Biophysica Acta (BBA) - General Subjects</italic>
<year>2012</year>
<volume>1820</volume>
<issue>10</issue>
<fpage>1656</fpage>
<lpage>1663</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagen.2012.06.015</pub-id>
<pub-id pub-id-type="other">2-s2.0-84863750795</pub-id>
<pub-id pub-id-type="pmid">22750202</pub-id>
</element-citation>
</ref>
<ref id="B91">
<label>91</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fakruddin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hossain</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>M. M.</given-names>
</name>
</person-group>
<article-title>Antimicrobial and antioxidant activities of <italic>Saccharomyces cerevisiae</italic> IFST062013, a potential probiotic</article-title>
<source/>
<italic toggle="yes">BMC Complementary and Alternative Medicine</italic>
<year>2017</year>
<volume>17</volume>
<issue>1</issue>
<fpage>p. 64</fpage>
<pub-id pub-id-type="doi">10.1186/s12906-017-1591-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-85009956155</pub-id>
<pub-id pub-id-type="pmid">28109187</pub-id>
</element-citation>
</ref>
<ref id="B92">
<label>92</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maccaferri</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Klinder</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Brigidi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Cavina</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Costabile</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Potential probiotic <italic>Kluyveromyces marxianus</italic> B0399 modulates the immune response in Caco-2 cells and peripheral blood mononuclear cells and impacts the human gut microbiota in an in vitro colonic model system</article-title>
<source/>
<italic toggle="yes">Applied and Environmental Microbiology</italic>
<year>2012</year>
<volume>78</volume>
<issue>4</issue>
<fpage>956</fpage>
<lpage>964</lpage>
<pub-id pub-id-type="doi">10.1128/AEM.06385-11</pub-id>
<pub-id pub-id-type="other">2-s2.0-84857090444</pub-id>
<pub-id pub-id-type="pmid">22156412</pub-id>
</element-citation>
</ref>
<ref id="B93">
<label>93</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>M. K.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Houde</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Effects of lactobacilli and an acidophilic fungus on the production performance and immune responses in broiler chickens</article-title>
<source/>
<italic toggle="yes">Poultry Science</italic>
<year>2004</year>
<volume>83</volume>
<issue>5</issue>
<fpage>788</fpage>
<lpage>795</lpage>
<pub-id pub-id-type="doi">10.1093/ps/83.5.788</pub-id>
<pub-id pub-id-type="other">2-s2.0-3042780323</pub-id>
<pub-id pub-id-type="pmid">15141837</pub-id>
</element-citation>
</ref>
<ref id="B94">
<label>94</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Markey</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shaban</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>E. R.</given-names>
</name>
<name>
<surname>Lemon</surname>
<given-names>K. P.</given-names>
</name>
<name>
<surname>Mecsas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kumamoto</surname>
<given-names>C. A.</given-names>
</name>
</person-group>
<article-title>Pre-colonization with the commensal fungus <italic>Candida albicans</italic> reduces murine susceptibility to <italic>Clostridium difficile</italic> infection</article-title>
<source/>
<italic toggle="yes">Gut Microbes</italic>
<year>2018</year>
<volume>9</volume>
<issue>6</issue>
<fpage>497</fpage>
<lpage>509</lpage>
<pub-id pub-id-type="doi">10.1080/19490976.2018.1465158</pub-id>
<pub-id pub-id-type="other">2-s2.0-85047892914</pub-id>
<pub-id pub-id-type="pmid">29667487</pub-id>
</element-citation>
</ref>
<ref id="B95">
<label>95</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diniz</surname>
<given-names>R. O.</given-names>
</name>
<name>
<surname>Garla</surname>
<given-names>L. K.</given-names>
</name>
<name>
<surname>Schneedorf</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Carvalho</surname>
<given-names>J. C. T.</given-names>
</name>
</person-group>
<article-title>Study of anti-inflammatory activity of Tibetan mushroom, a symbiotic culture of bacteria and fungi encapsulated into a polysaccharide matrix</article-title>
<source/>
<italic toggle="yes">Pharmacological Research</italic>
<year>2003</year>
<volume>47</volume>
<issue>1</issue>
<fpage>49</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1016/S1043-6618(02)00240-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-0037285064</pub-id>
<pub-id pub-id-type="pmid">12526861</pub-id>
</element-citation>
</ref>
<ref id="B96">
<label>96</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Takebe</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Schofield</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. M.</given-names>
</name>
</person-group>
<article-title>Therapeutic effects of a fermented soy product on peanut hypersensitivity is associated with modulation of T-helper type 1 and T-helper type 2 responses</article-title>
<source/>
<italic toggle="yes">Clinical &amp; Experimental Allergy</italic>
<year>2008</year>
<volume>38</volume>
<issue>11</issue>
<fpage>1808</fpage>
<lpage>1818</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2222.2008.03075.x</pub-id>
<pub-id pub-id-type="other">2-s2.0-54849424950</pub-id>
<pub-id pub-id-type="pmid">18705693</pub-id>
</element-citation>
</ref>
<ref id="B97">
<label>97</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abraham</surname>
<given-names>B. P.</given-names>
</name>
<name>
<surname>Quigley</surname>
<given-names>E. M. M.</given-names>
</name>
</person-group>
<article-title>Probiotics in inflammatory bowel disease</article-title>
<source/>
<italic toggle="yes">Gastroenterology Clinics of North America</italic>
<year>2017</year>
<volume>46</volume>
<issue>4</issue>
<fpage>769</fpage>
<lpage>782</lpage>
<pub-id pub-id-type="doi">10.1016/j.gtc.2017.08.003</pub-id>
<pub-id pub-id-type="other">2-s2.0-85030481903</pub-id>
<pub-id pub-id-type="pmid">29173520</pub-id>
</element-citation>
</ref>
<ref id="B98">
<label>98</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shanahan</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>A commentary on the safety of probiotics</article-title>
<source/>
<italic toggle="yes">Gastroenterology Clinics of North America</italic>
<year>2012</year>
<volume>41</volume>
<issue>4</issue>
<fpage>869</fpage>
<lpage>876</lpage>
<pub-id pub-id-type="doi">10.1016/j.gtc.2012.08.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-84867944463</pub-id>
<pub-id pub-id-type="pmid">23101692</pub-id>
</element-citation>
</ref>
<ref id="B99">
<label>99</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krag</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Munkholm</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Israelsen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>von Ryberg</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>K. K.</given-names>
</name>
<name>
<surname>Bendtsen</surname>
<given-names>F.</given-names>
</name>
</person-group>
<article-title>Profermin is efficacious in patients with active ulcerative colitis—a randomized controlled trial</article-title>
<source/>
<italic toggle="yes">Inflammatory Bowel Diseases</italic>
<year>2013</year>
<volume>19</volume>
<issue>12</issue>
<fpage>2584</fpage>
<lpage>2592</lpage>
<pub-id pub-id-type="doi">10.1097/01.MIB.0000437046.26036.db</pub-id>
<pub-id pub-id-type="other">2-s2.0-84888315007</pub-id>
<pub-id pub-id-type="pmid">24108114</pub-id>
</element-citation>
</ref>
<ref id="B100">
<label>100</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fedorak</surname>
<given-names>R. N.</given-names>
</name>
<name>
<surname>Feagan</surname>
<given-names>B. G.</given-names>
</name>
<name>
<surname>Hotte</surname>
<given-names>N.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence after surgery for Crohn’s disease</article-title>
<source/>
<italic toggle="yes">Clinical Gastroenterology and Hepatology</italic>
<year>2015</year>
<volume>13</volume>
<issue>5</issue>
<fpage>928</fpage>
<lpage>935.e2</lpage>
<pub-id pub-id-type="doi">10.1016/j.cgh.2014.10.031</pub-id>
<pub-id pub-id-type="other">2-s2.0-84927909282</pub-id>
<pub-id pub-id-type="pmid">25460016</pub-id>
</element-citation>
</ref>
<ref id="B101">
<label>101</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoshimatsu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yamada</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Furukawa</surname>
<given-names>R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis</article-title>
<source/>
<italic toggle="yes">World Journal of Gastroenterology</italic>
<year>2015</year>
<volume>21</volume>
<issue>19</issue>
<fpage>5985</fpage>
<lpage>5994</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v21.i19.5985</pub-id>
<pub-id pub-id-type="other">2-s2.0-84929630147</pub-id>
<pub-id pub-id-type="pmid">26019464</pub-id>
</element-citation>
</ref>
<ref id="B102">
<label>102</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamaki</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Nakase</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Inoue</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy of probiotic treatment with <italic>Bifidobacterium longum 536</italic> for induction of remission in active ulcerative colitis: a randomized, double-blinded, placebo-controlled multicenter trial</article-title>
<source/>
<italic toggle="yes">Digestive Endoscopy</italic>
<year>2016</year>
<volume>28</volume>
<issue>1</issue>
<fpage>67</fpage>
<lpage>74</lpage>
<pub-id pub-id-type="doi">10.1111/den.12553</pub-id>
<pub-id pub-id-type="other">2-s2.0-84956743698</pub-id>
<pub-id pub-id-type="pmid">26418574</pub-id>
</element-citation>
</ref>
<ref id="B103">
<label>103</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahmed</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Molbak</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Leser</surname>
<given-names>T. D.</given-names>
</name>
<name>
<surname>MacFie</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Impact of probiotics on colonic microflora in patients with colitis: a prospective double blind randomised crossover study</article-title>
<source/>
<italic toggle="yes">International Journal of Surgery</italic>
<year>2013</year>
<volume>11</volume>
<issue>10</issue>
<fpage>1131</fpage>
<lpage>1136</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijsu.2013.08.019</pub-id>
<pub-id pub-id-type="other">2-s2.0-84889094301</pub-id>
<pub-id pub-id-type="pmid">24060951</pub-id>
</element-citation>
</ref>
<ref id="B104">
<label>104</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bourreille</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Cadiot</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Le Dreau</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>Saccharomyces boulardii</italic> does not prevent relapse of Crohn’s disease</article-title>
<source/>
<italic toggle="yes">Clinical Gastroenterology and Hepatology</italic>
<year>2013</year>
<volume>11</volume>
<issue>8</issue>
<fpage>982</fpage>
<lpage>987</lpage>
<pub-id pub-id-type="doi">10.1016/j.cgh.2013.02.021</pub-id>
<pub-id pub-id-type="other">2-s2.0-84880587709</pub-id>
<pub-id pub-id-type="pmid">23466709</pub-id>
</element-citation>
</ref>
<ref id="B105">
<label>105</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petersen</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Mirsepasi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Halkjær</surname>
<given-names>S. I.</given-names>
</name>
<name>
<surname>Mortensen</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Nordgaard-Lassen</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Krogfelt</surname>
<given-names>K. A.</given-names>
</name>
</person-group>
<article-title>Ciprofloxacin and probiotic <italic>Escherichia coli</italic> Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial</article-title>
<source/>
<italic toggle="yes">Journal of Crohn's and Colitis</italic>
<year>2014</year>
<volume>8</volume>
<issue>11</issue>
<fpage>1498</fpage>
<lpage>1505</lpage>
<pub-id pub-id-type="doi">10.1016/j.crohns.2014.06.001</pub-id>
<pub-id pub-id-type="other">2-s2.0-84927799957</pub-id>
<pub-id pub-id-type="pmid">24972748</pub-id>
</element-citation>
</ref>
<ref id="B106">
<label>106</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derwa</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gracie</surname>
<given-names>D. J.</given-names>
</name>
<name>
<surname>Hamlin</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Ford</surname>
<given-names>A. C.</given-names>
</name>
</person-group>
<article-title>Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease</article-title>
<source/>
<italic toggle="yes">Alimentary Pharmacology &amp; Therapeutics</italic>
<year>2017</year>
<volume>46</volume>
<issue>4</issue>
<fpage>389</fpage>
<lpage>400</lpage>
<pub-id pub-id-type="doi">10.1111/apt.14203</pub-id>
<pub-id pub-id-type="other">2-s2.0-85021387293</pub-id>
<pub-id pub-id-type="pmid">28653751</pub-id>
</element-citation>
</ref>
<ref id="B107">
<label>107</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sindhu</surname>
<given-names>K. N. C.</given-names>
</name>
<name>
<surname>Sowmyanarayanan</surname>
<given-names>T. V.</given-names>
</name>
<name>
<surname>Paul</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immune response and intestinal permeability in children with acute gastroenteritis treated with <italic>Lactobacillus rhamnosus</italic> GG: a randomized, double-blind, placebo-controlled trial</article-title>
<source/>
<italic toggle="yes">Clinical Infectious Diseases</italic>
<year>2014</year>
<volume>58</volume>
<issue>8</issue>
<fpage>1107</fpage>
<lpage>1115</lpage>
<pub-id pub-id-type="doi">10.1093/cid/ciu065</pub-id>
<pub-id pub-id-type="other">2-s2.0-84897446350</pub-id>
<pub-id pub-id-type="pmid">24501384</pub-id>
</element-citation>
</ref>
<ref id="B108">
<label>108</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maldonado-Lobón</surname>
<given-names>J. A.</given-names>
</name>
<name>
<surname>Gil-Campos</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Maldonado</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Long-term safety of early consumption of <italic>Lactobacillus fermentum</italic> CECT5716: a 3-year follow-up of a randomized controlled trial</article-title>
<source/>
<italic toggle="yes">Pharmacological Research</italic>
<year>2015</year>
<volume>95-96</volume>
<issue>96</issue>
<fpage>12</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/j.phrs.2015.01.006</pub-id>
<pub-id pub-id-type="other">2-s2.0-84925835264</pub-id>
<pub-id pub-id-type="pmid">25697549</pub-id>
</element-citation>
</ref>
<ref id="B109">
<label>109</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mimura</surname>
<given-names>M. A. M.</given-names>
</name>
<name>
<surname>Borra</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Hirata</surname>
<given-names>C. H. W.</given-names>
</name>
<name>
<surname>de Oliveira Penido</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Immune response of patients with recurrent aphthous stomatitis challenged with a symbiotic</article-title>
<source/>
<italic toggle="yes">Journal of Oral Pathology &amp; Medicine</italic>
<year>2017</year>
<volume>46</volume>
<issue>9</issue>
<fpage>821</fpage>
<lpage>828</lpage>
<pub-id pub-id-type="doi">10.1111/jop.12621</pub-id>
<pub-id pub-id-type="other">2-s2.0-85030331413</pub-id>
<pub-id pub-id-type="pmid">28776757</pub-id>
</element-citation>
</ref>
<ref id="B110">
<label>110</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savino</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Garro</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Montanari</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Galliano</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bergallo</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Crying time and ROR<italic>γ</italic>/FOXP3 expression in <italic>Lactobacillus reuteri DSM17938</italic>-treated infants with colic: a randomized trial</article-title>
<source/>
<italic toggle="yes">The Journal of Pediatrics</italic>
<year>2018</year>
<volume>192</volume>
<fpage>171</fpage>
<lpage>177.e1</lpage>
<pub-id pub-id-type="doi">10.1016/j.jpeds.2017.08.062</pub-id>
<pub-id pub-id-type="other">2-s2.0-85030464899</pub-id>
<pub-id pub-id-type="pmid">28969887</pub-id>
</element-citation>
</ref>
<ref id="B111">
<label>111</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dennis-Wall</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Culpepper</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Nieves</surname>
<given-names>C.</given-names>
<suffix>Jr.</suffix>
</name>
<etal></etal>
</person-group>
<article-title>Probiotics (<italic>Lactobacillus gasseri</italic> KS-13, <italic>Bifidobacterium bifidum</italic> G9-1, and <italic>Bifidobacterium longum</italic> MM-2) improve rhinoconjunctivitis-specific quality of life in individuals with seasonal allergies: a double-blind, placebo-controlled, randomized trial</article-title>
<source/>
<italic toggle="yes">The American Journal of Clinical Nutrition</italic>
<year>2017</year>
<volume>105</volume>
<issue>3</issue>
<fpage>758</fpage>
<lpage>767</lpage>
<pub-id pub-id-type="doi">10.3945/ajcn.116.140012</pub-id>
<pub-id pub-id-type="other">2-s2.0-85020815683</pub-id>
<pub-id pub-id-type="pmid">28228426</pub-id>
</element-citation>
</ref>
<ref id="B112">
<label>112</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Identification of atopic dermatitis phenotypes with good responses to probiotics (<italic>Lactobacillus plantarum</italic> CJLP133) in children</article-title>
<source/>
<italic toggle="yes">Beneficial Microbes</italic>
<year>2017</year>
<volume>8</volume>
<issue>5</issue>
<fpage>755</fpage>
<lpage>761</lpage>
<pub-id pub-id-type="doi">10.3920/BM2017.0034</pub-id>
<pub-id pub-id-type="other">2-s2.0-85031432066</pub-id>
<pub-id pub-id-type="pmid">29035111</pub-id>
</element-citation>
</ref>
<ref id="B113">
<label>113</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sheikhi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Giti</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Heibor</surname>
<given-names>M. R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lactobacilus delbrueckii subsp. bulgaricus modulates the secretion of Th1/Th2 and Treg cell-related cytokines by PBMCs from patients with atopic dermatitis</article-title>
<source/>
<italic toggle="yes">Drug Research</italic>
<year>2017</year>
<volume>67</volume>
<issue>12</issue>
<fpage>724</fpage>
<lpage>729</lpage>
<pub-id pub-id-type="doi">10.1055/s-0043-117612</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029754192</pub-id>
<pub-id pub-id-type="pmid">28898911</pub-id>
</element-citation>
</ref>
<ref id="B114">
<label>114</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rø</surname>
<given-names>A. D. B.</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Rø</surname>
<given-names>T. B.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Reduced Th22 cell proportion and prevention of atopic dermatitis in infants following maternal probiotic supplementation</article-title>
<source/>
<italic toggle="yes">Clinical &amp; Experimental Allergy</italic>
<year>2017</year>
<volume>47</volume>
<issue>8</issue>
<fpage>1014</fpage>
<lpage>1021</lpage>
<pub-id pub-id-type="doi">10.1111/cea.12930</pub-id>
<pub-id pub-id-type="other">2-s2.0-85018637976</pub-id>
<pub-id pub-id-type="pmid">28346719</pub-id>
</element-citation>
</ref>
<ref id="B115">
<label>115</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Singh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sarangi</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Goel</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effect of administration of a probiotic preparation on gut microbiota and immune response in healthy women in India: an open-label, single-arm pilot study</article-title>
<source/>
<italic toggle="yes">BMC Gastroenterology</italic>
<year>2018</year>
<volume>18</volume>
<issue>1</issue>
<fpage>p. 85</fpage>
<pub-id pub-id-type="doi">10.1186/s12876-018-0819-6</pub-id>
<pub-id pub-id-type="other">2-s2.0-85048617256</pub-id>
<pub-id pub-id-type="pmid">29907093</pub-id>
</element-citation>
</ref>
<ref id="B116">
<label>116</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Yoo</surname>
<given-names>H. J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Consumption of dairy yogurt containing <italic>Lactobacillus paracasei</italic> ssp. <italic>paracasei</italic>, <italic>Bifidobacterium animalis</italic> ssp. <italic>lactis</italic> and heat-treated <italic>Lactobacillus plantarum</italic> improves immune function including natural killer cell activity</article-title>
<source/>
<italic toggle="yes">Nutrients</italic>
<year>2017</year>
<volume>9</volume>
<issue>6</issue>
<fpage>p. 558</fpage>
<pub-id pub-id-type="doi">10.3390/nu9060558</pub-id>
<pub-id pub-id-type="other">2-s2.0-85020291803</pub-id>
</element-citation>
</ref>
<ref id="B117">
<label>117</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shukla</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Gaur</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Aggarwal</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Effect of probiotics on clinical and immune parameters in enthesitis-related arthritis category of juvenile idiopathic arthritis</article-title>
<source/>
<italic toggle="yes">Clinical and Experimental Immunology</italic>
<year>2016</year>
<volume>185</volume>
<issue>3</issue>
<fpage>301</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="doi">10.1111/cei.12818</pub-id>
<pub-id pub-id-type="other">2-s2.0-84983268272</pub-id>
<pub-id pub-id-type="pmid">27238895</pub-id>
</element-citation>
</ref>
<ref id="B118">
<label>118</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibrahim</surname>
<given-names>N. S.</given-names>
</name>
<name>
<surname>Ooi</surname>
<given-names>F. K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>C. K.</given-names>
</name>
<name>
<surname>Muhamad</surname>
<given-names>A. S.</given-names>
</name>
</person-group>
<article-title>Effects of probiotics supplementation and circuit training on immune responses among sedentary young males</article-title>
<source/>
<italic toggle="yes">The Journal of Sports Medicine and Physical Fitness</italic>
<year>2018</year>
<volume>58</volume>
<issue>7-8</issue>
<fpage>1102</fpage>
<lpage>1109</lpage>
<pub-id pub-id-type="doi">10.23736/S0022-4707.17.07742-8</pub-id>
<pub-id pub-id-type="other">2-s2.0-85049437455</pub-id>
<pub-id pub-id-type="pmid">28677946</pub-id>
</element-citation>
</ref>
<ref id="B119">
<label>119</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Komano</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Naito</surname>
<given-names>H.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Efficacy of heat-killed <italic>Lactococcus lactis</italic> JCM 5805 on immunity and fatigue during consecutive high intensity exercise in male athletes: a randomized, placebo-controlled, double-blinded trial</article-title>
<source/>
<italic toggle="yes">Journal of the International Society of Sports Nutrition</italic>
<year>2018</year>
<volume>15</volume>
<issue>1</issue>
<pub-id pub-id-type="doi">10.1186/s12970-018-0244-9</pub-id>
<pub-id pub-id-type="other">2-s2.0-85051037205</pub-id>
</element-citation>
</ref>
<ref id="B120">
<label>120</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bowman</surname>
<given-names>K. A.</given-names>
</name>
<name>
<surname>Broussard</surname>
<given-names>E. K.</given-names>
</name>
<name>
<surname>Surawicz</surname>
<given-names>C. M.</given-names>
</name>
</person-group>
<article-title>Fecal microbiota transplantation: current clinical efficacy and future prospects</article-title>
<source/>
<italic toggle="yes">Clinical and Experimental Gastroenterology</italic>
<year>2015</year>
<volume>8</volume>
<fpage>285</fpage>
<lpage>291</lpage>
<pub-id pub-id-type="doi">10.2147/CEG.S61305</pub-id>
<pub-id pub-id-type="other">2-s2.0-84945942021</pub-id>
<pub-id pub-id-type="pmid">26566371</pub-id>
</element-citation>
</ref>
<ref id="B121">
<label>121</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bafeta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yavchitz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Riveros</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Batista</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ravaud</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Methods and reporting studies assessing fecal microbiota transplantation: a systematic review</article-title>
<source/>
<italic toggle="yes">Annals of Internal Medicine</italic>
<year>2017</year>
<volume>167</volume>
<issue>1</issue>
<fpage>34</fpage>
<lpage>39</lpage>
<pub-id pub-id-type="doi">10.7326/M16-2810</pub-id>
<pub-id pub-id-type="other">2-s2.0-85021822684</pub-id>
<pub-id pub-id-type="pmid">28531908</pub-id>
</element-citation>
</ref>
<ref id="B122">
<label>122</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacob</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cohen-Mekelburg</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Single delivery of high-diversity fecal microbiota preparation by colonoscopy is safe and effective in increasing microbial diversity in active ulcerative colitis</article-title>
<source/>
<italic toggle="yes">Inflammatory Bowel Diseases</italic>
<year>2017</year>
<volume>23</volume>
<issue>6</issue>
<fpage>903</fpage>
<lpage>911</lpage>
<pub-id pub-id-type="doi">10.1097/MIB.0000000000001132</pub-id>
<pub-id pub-id-type="other">2-s2.0-85019701654</pub-id>
<pub-id pub-id-type="pmid">28445246</pub-id>
</element-citation>
</ref>
<ref id="B123">
<label>123</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goyal</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yeh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>B. R.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Safety, clinical response, and microbiome findings following fecal microbiota transplant in children with inflammatory bowel disease</article-title>
<source/>
<italic toggle="yes">Inflammatory Bowel Diseases</italic>
<year>2018</year>
<volume>24</volume>
<issue>2</issue>
<fpage>410</fpage>
<lpage>421</lpage>
<pub-id pub-id-type="doi">10.1093/ibd/izx035</pub-id>
<pub-id pub-id-type="pmid">29361092</pub-id>
</element-citation>
</ref>
<ref id="B124">
<label>124</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karolewska-Bochenek</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Grzesiowski</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Banaszkiewicz</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>A two-week fecal microbiota transplantation course in pediatric patients with inflammatory bowel disease</article-title>
<source/>
<italic toggle="yes">Advances in Experimental Medicine and Biology</italic>
<year>2017</year>
<volume>1047</volume>
<fpage>81</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="doi">10.1007/5584_2017_123</pub-id>
<pub-id pub-id-type="other">2-s2.0-85047527394</pub-id>
</element-citation>
</ref>
<ref id="B125">
<label>125</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pai</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Popov</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Protocol for a randomised, placebo-controlled pilot study for assessing feasibility and efficacy of faecal microbiota transplantation in a paediatric ulcerative colitis population: PediFETCh trial</article-title>
<source/>
<italic toggle="yes">BMJ Open</italic>
<year>2017</year>
<volume>7</volume>
<issue>8, article e016698</issue>
<pub-id pub-id-type="doi">10.1136/bmjopen-2017-016698</pub-id>
<pub-id pub-id-type="other">2-s2.0-85046990579</pub-id>
<pub-id pub-id-type="pmid">28827258</pub-id>
</element-citation>
</ref>
<ref id="B126">
<label>126</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meighani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hart</surname>
<given-names>B. R.</given-names>
</name>
<name>
<surname>Bourgi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>John</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ramesh</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Outcomes of fecal microbiota transplantation for <italic>Clostridium difficile</italic> infection in patients with inflammatory bowel disease</article-title>
<source/>
<italic toggle="yes">Digestive Diseases and Sciences</italic>
<year>2017</year>
<volume>62</volume>
<issue>10</issue>
<fpage>2870</fpage>
<lpage>2875</lpage>
<pub-id pub-id-type="doi">10.1007/s10620-017-4580-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-85018275851</pub-id>
<pub-id pub-id-type="pmid">28451916</pub-id>
</element-citation>
</ref>
<ref id="B127">
<label>127</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khanna</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vazquez-Baeza</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>González</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Changes in microbial ecology after fecal microbiota transplantation for recurrent <italic>C. difficile</italic> infection affected by underlying inflammatory bowel disease</article-title>
<source/>
<italic toggle="yes">Microbiome</italic>
<year>2017</year>
<volume>5</volume>
<issue>1</issue>
<pub-id pub-id-type="doi">10.1186/s40168-017-0269-3</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029744525</pub-id>
</element-citation>
</ref>
<ref id="B128">
<label>128</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mintz</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Khair</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Grewal</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent <italic>Clostridium difficile</italic> infection and/or ulcerative colitis</article-title>
<source/>
<italic toggle="yes">PLoS One</italic>
<year>2018</year>
<volume>13</volume>
<issue>1, article e0190997</issue>
<pub-id pub-id-type="doi">10.1371/journal.pone.0190997</pub-id>
<pub-id pub-id-type="other">2-s2.0-85041210949</pub-id>
<pub-id pub-id-type="pmid">29385143</pub-id>
</element-citation>
</ref>
<ref id="B129">
<label>129</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zmora</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zilberman-Schapira</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Suez</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features</article-title>
<source/>
<italic toggle="yes">Cell</italic>
<year>2018</year>
<volume>174</volume>
<issue>6</issue>
<fpage>1388</fpage>
<lpage>1405.e21</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2018.08.041</pub-id>
<pub-id pub-id-type="other">2-s2.0-85052760428</pub-id>
<pub-id pub-id-type="pmid">30193112</pub-id>
</element-citation>
</ref>
<ref id="B130">
<label>130</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zmora</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zilberman-Schapira</surname>
<given-names>G.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Post-antibiotic gut mucosal microbiome reconstitution is impaired by probiotics and improved by autologous FMT</article-title>
<source/>
<italic toggle="yes">Cell</italic>
<year>2018</year>
<volume>174</volume>
<issue>6</issue>
<fpage>1406</fpage>
<lpage>1423.e16</lpage>
<pub-id pub-id-type="doi">10.1016/j.cell.2018.08.047</pub-id>
<pub-id pub-id-type="other">2-s2.0-85052739697</pub-id>
<pub-id pub-id-type="pmid">30193113</pub-id>
</element-citation>
</ref>
<ref id="B131">
<label>131</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fischer</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sipe</surname>
<given-names>B. W.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>N. A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated <italic>Clostridium difficile</italic> infection: description of a protocol with high success rate</article-title>
<source/>
<italic toggle="yes">Alimentary Pharmacology &amp; Therapeutics</italic>
<year>2015</year>
<volume>42</volume>
<issue>4</issue>
<fpage>470</fpage>
<lpage>476</lpage>
<pub-id pub-id-type="doi">10.1111/apt.13290</pub-id>
<pub-id pub-id-type="other">2-s2.0-85006428014</pub-id>
<pub-id pub-id-type="pmid">26096320</pub-id>
</element-citation>
</ref>
<ref id="B132">
<label>132</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>T.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Fecal microbiota transplantation cured epilepsy in a case with Crohn’s disease: the first report</article-title>
<source/>
<italic toggle="yes">World Journal of Gastroenterology</italic>
<year>2017</year>
<volume>23</volume>
<issue>19</issue>
<fpage>3565</fpage>
<lpage>3568</lpage>
<pub-id pub-id-type="doi">10.3748/wjg.v23.i19.3565</pub-id>
<pub-id pub-id-type="other">2-s2.0-85019859955</pub-id>
<pub-id pub-id-type="pmid">28596693</pub-id>
</element-citation>
</ref>
<ref id="B133">
<label>133</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paramsothy</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kamm</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Kaakoush</surname>
<given-names>N. O.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial</article-title>
<source/>
<italic toggle="yes">The Lancet</italic>
<year>2017</year>
<volume>389</volume>
<issue>10075</issue>
<fpage>1218</fpage>
<lpage>1228</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(17)30182-4</pub-id>
<pub-id pub-id-type="other">2-s2.0-85012869662</pub-id>
</element-citation>
</ref>
<ref id="B134">
<label>134</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>J.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn’s disease complicated with inflammatory mass</article-title>
<source/>
<italic toggle="yes">Scientific Reports</italic>
<year>2017</year>
<volume>7</volume>
<issue>1</issue>
<fpage>p. 4753</fpage>
<pub-id pub-id-type="doi">10.1038/s41598-017-04984-z</pub-id>
<pub-id pub-id-type="other">2-s2.0-85021992003</pub-id>
</element-citation>
</ref>
<ref id="B135">
<label>135</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis</article-title>
<source/>
<italic toggle="yes">Journal of Translational Medicine</italic>
<year>2015</year>
<volume>13</volume>
<issue>1</issue>
<fpage>p. 298</fpage>
<pub-id pub-id-type="doi">10.1186/s12967-015-0646-2</pub-id>
<pub-id pub-id-type="other">2-s2.0-84941273178</pub-id>
</element-citation>
</ref>
<ref id="B136">
<label>136</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Peres</surname>
<given-names>A. G.</given-names>
</name>
<name>
<surname>Mfuna Endam</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cousineau</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Madrenas</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Desrosiers</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Topical probiotics as a therapeutic alternative for chronic rhinosinusitis: a preclinical proof of concept</article-title>
<source/>
<italic toggle="yes">American Journal of Rhinology &amp; Allergy</italic>
<year>2016</year>
<volume>30</volume>
<issue>6</issue>
<fpage>202</fpage>
<lpage>205</lpage>
<pub-id pub-id-type="doi">10.2500/ajra.2016.30.4372</pub-id>
<pub-id pub-id-type="other">2-s2.0-84995896938</pub-id>
<pub-id pub-id-type="pmid">28124641</pub-id>
</element-citation>
</ref>
<ref id="B137">
<label>137</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tariq</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Pardi</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Tosh</surname>
<given-names>P. K.</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>R. C.</given-names>
</name>
<name>
<surname>Razonable</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Khanna</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Fecal microbiota transplantation for recurrent <italic>Clostridium difficile</italic> infection reduces recurrent urinary tract infection frequency</article-title>
<source/>
<italic toggle="yes">Clinical Infectious Diseases</italic>
<year>2017</year>
<volume>65</volume>
<issue>10</issue>
<fpage>1745</fpage>
<lpage>1747</lpage>
<pub-id pub-id-type="doi">10.1093/cid/cix618</pub-id>
<pub-id pub-id-type="other">2-s2.0-85032739811</pub-id>
<pub-id pub-id-type="pmid">29020210</pub-id>
</element-citation>
</ref>
<ref id="B138">
<label>138</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Prince</surname>
<given-names>A. L.</given-names>
</name>
<name>
<surname>Antony</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Seferovic</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Aagaard</surname>
<given-names>K. M.</given-names>
</name>
</person-group>
<article-title>Maturation of the infant microbiome community structure and function across multiple body sites and in relation to mode of delivery</article-title>
<source/>
<italic toggle="yes">Nature Medicine</italic>
<year>2017</year>
<volume>23</volume>
<issue>3</issue>
<fpage>314</fpage>
<lpage>326</lpage>
<pub-id pub-id-type="doi">10.1038/nm.4272</pub-id>
<pub-id pub-id-type="other">2-s2.0-85010902656</pub-id>
<pub-id pub-id-type="pmid">28112736</pub-id>
</element-citation>
</ref>
<ref id="B139">
<label>139</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Azad</surname>
<given-names>M. A. K.</given-names>
</name>
<name>
<surname>Sarker</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wan</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Immunomodulatory effects of probiotics on cytokine profiles</article-title>
<source/>
<italic toggle="yes">BioMed Research International</italic>
<year>2018</year>
<volume>2018</volume>
<fpage>10</fpage>
<pub-id pub-id-type="publisher-id">8063647</pub-id>
<pub-id pub-id-type="doi">10.1155/2018/8063647</pub-id>
</element-citation>
</ref>
<ref id="B140">
<label>140</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Castro-Bravo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Wells</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Margolles</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ruas-Madiedo</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Interactions of surface exopolysaccharides from <italic>Bifidobacterium</italic> and <italic>Lactobacillus</italic> within the intestinal environment</article-title>
<source/>
<italic toggle="yes">Frontiers in Microbiology</italic>
<year>2018</year>
<volume>9</volume>
<pub-id pub-id-type="doi">10.3389/fmicb.2018.02426</pub-id>
<pub-id pub-id-type="other">2-s2.0-85055339767</pub-id>
</element-citation>
</ref>
<ref id="B141">
<label>141</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chapot-Chartier</surname>
<given-names>M.-P.</given-names>
</name>
<name>
<surname>Kulakauskas</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Cell wall structure and function in lactic acid bacteria</article-title>
<source/>
<italic toggle="yes">Microbial Cell Factories</italic>
<year>2014</year>
<volume>13, article S9</volume>
<issue>Supplement 1</issue>
<pub-id pub-id-type="doi">10.1186/1475-2859-13-s1-s9</pub-id>
<pub-id pub-id-type="other">2-s2.0-84906834067</pub-id>
</element-citation>
</ref>
<ref id="B142">
<label>142</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Marco</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sichetti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Muradyan</surname>
<given-names>D.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Probiotic cell-free supernatants exhibited anti-inflammatory and antioxidant activity on human gut epithelial cells and macrophages stimulated with LPS</article-title>
<source/>
<italic toggle="yes">Evidence-Based Complementary and Alternative Medicine</italic>
<year>2018</year>
<volume>2018</volume>
<fpage>12</fpage>
<pub-id pub-id-type="publisher-id">1756308</pub-id>
<pub-id pub-id-type="doi">10.1155/2018/1756308</pub-id>
<pub-id pub-id-type="other">2-s2.0-85050274465</pub-id>
</element-citation>
</ref>
<ref id="B143">
<label>143</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Immunomodulation and signaling mechanism of <italic>Lactobacillus rhamnosus</italic> GG and its components on porcine intestinal epithelial cells stimulated by lipopolysaccharide</article-title>
<source/>
<italic toggle="yes">Journal of Microbiology, Immunology and Infection</italic>
<year>2017</year>
<volume>50</volume>
<issue>5</issue>
<fpage>700</fpage>
<lpage>713</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmii.2015.05.002</pub-id>
<pub-id pub-id-type="other">2-s2.0-84930466227</pub-id>
</element-citation>
</ref>
<ref id="B144">
<label>144</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guglielmetti</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zanoni</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Balzaretti</surname>
<given-names>S.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Murein lytic enzyme TgaA of <italic>Bifidobacterium bifidum</italic> MIMBb75 modulates dendritic cell maturation through its cysteine- and histidine-dependent amidohydrolase/peptidase (CHAP) amidase domain</article-title>
<source/>
<italic toggle="yes">Applied and Environmental Microbiology</italic>
<year>2014</year>
<volume>80</volume>
<issue>17</issue>
<fpage>5170</fpage>
<lpage>5177</lpage>
<pub-id pub-id-type="doi">10.1128/AEM.00761-14</pub-id>
<pub-id pub-id-type="other">2-s2.0-84905922553</pub-id>
<pub-id pub-id-type="pmid">24814791</pub-id>
</element-citation>
</ref>
<ref id="B145">
<label>145</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hidalgo-Cantabrana</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Moro-García</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Blanco-Míguez</surname>
<given-names>A.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>In silico screening of the human gut metaproteome identifies Th17-promoting peptides encrypted in proteins of commensal bacteria</article-title>
<source/>
<italic toggle="yes">Frontiers in Microbiology</italic>
<year>2017</year>
<volume>8</volume>
<fpage>p. 1726</fpage>
<pub-id pub-id-type="doi">10.3389/fmicb.2017.01726</pub-id>
<pub-id pub-id-type="other">2-s2.0-85029222764</pub-id>
</element-citation>
</ref>
<ref id="B146">
<label>146</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiavi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Gleinser</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Molloy</surname>
<given-names>E.</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The surface-associated exopolysaccharide of <italic>Bifidobacterium longum</italic> 35624 plays an essential role in dampening host proinflammatory responses and repressing local T<sub>H</sub>17 responses</article-title>
<source/>
<italic toggle="yes">Applied and Environmental Microbiology</italic>
<year>2016</year>
<volume>82</volume>
<issue>24</issue>
<fpage>7185</fpage>
<lpage>7196</lpage>
<pub-id pub-id-type="doi">10.1128/AEM.02238-16</pub-id>
<pub-id pub-id-type="other">2-s2.0-84997482223</pub-id>
<pub-id pub-id-type="pmid">27736791</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="fig1" orientation="portrait" position="float">
<label>Figure 1</label>
<caption>
<p>The dual functions of probiotics on the immune system in in vitro and animal experiments. ↑: activity enhanced or quantity increased; ↓: activity reduced or quantity decreased. Immune cell: immune cells on which probiotics directly stimulate. Effects: the immunological effect generated by immune cells stimulated by probiotics, mainly including the regulation on cytokines and the differentiation of related immune cell subpopulations.</p>
</caption>
<graphic xlink:href="JIR2019-1603758.001"></graphic>
</fig>
<fig id="fig2" orientation="portrait" position="float">
<label>Figure 2</label>
<caption>
<p>Effects of probiotics on the Th17/Treg balance. Treg can be increased by probiotics, such as <italic>Lactobacillus</italic> (<italic>plantarum</italic>, <italic>fermentum</italic>, <italic>salivarius</italic>, <italic>acidophilus</italic>, <italic>casei</italic>, and <italic>rhamnosus</italic>), <italic>Bifidobacterium</italic> (<italic>animalis</italic>, <italic>infantis</italic>, <italic>longum</italic>, <italic>lactis</italic>, and <italic>breve</italic>), and <italic>Bacillus coagulans</italic>, <italic>Clostridium butyricum</italic>, <italic>Weissella cibaria</italic>, <italic>Enterococcus durans</italic>, and <italic>Prevotella histicola</italic>. Th17 can be increased by probiotics, such as <italic>Lactobacillus plantarum</italic>, <italic>Bifidobacterium adolescentis</italic>. Conversely, Th17 can be decreased by probiotics, such as <italic>Lactobacillus</italic> (<italic>delbrueckii</italic>, <italic>acidophilus</italic>, and <italic>rhamnosus</italic>), <italic>Bifidobacterium breve</italic>, and <italic>Enterococcus faecalis</italic> and <italic>Prevotella histicola</italic>.</p>
</caption>
<graphic xlink:href="JIR2019-1603758.002"></graphic>
</fig>
<table-wrap id="tab1" orientation="portrait" position="float">
<label>Table 1</label>
<caption>
<p>The immunomodulatory components of Lactobacillus and Bifidobacterium.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Probiotic genera</th>
<th align="center" colspan="1" rowspan="1">Probiotic strains</th>
<th align="left" colspan="1" rowspan="1">Immunomodulatory components of probiotics</th>
<th align="center" colspan="1" rowspan="1">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Lactobacillus</italic>
</td>
<td align="center" colspan="1" rowspan="1">
<italic>L. acidophilus</italic>, <italic>L. amylovorus</italic>, <italic>L. bulgaricus</italic>, <italic>L. crispatus</italic>, <italic>L. casei</italic>, <italic>L. gasseri</italic>, <italic>L. helveticus</italic>, <italic>L. johnsonii</italic>, <italic>L. pentosus</italic>, <italic>L. reuteri</italic>, <italic>L. paracasei</italic>, <italic>L. plantarum</italic>, <italic>L. rhamnosus</italic></td>
<td align="left" colspan="1" rowspan="1">(1) Lipoteichoic acid stimulates NO synthase<break></break>(2) Lipoproteins and LTA can potentially signal through binding to TLR2 in combination with TLR6<break></break>(3) Unmethylated DNA fragments containing CpG motifs mediate anti-inflammatory effects via TLR9 signaling at the epithelial surface<break></break>(4) Highly O-acetylated peptidoglycan might affect the release of NLR stimulating PG fragments and innate immune responses of antigen-presenting cells such as dendritic cells and macrophages<break></break>(5) EPS and other cell wall polysaccharides could be recognized by CLRs that are involved in the recognition and capture of antigens by antigen-presenting cells such as dendritic cells and macrophages</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B139">139</xref>–<xref ref-type="bibr" rid="B143">143</xref>]</td>
</tr>
<tr>
<td align="center" colspan="4" rowspan="1">
<hr/>
</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>Bifidobacterium</italic>
</td>
<td align="center" colspan="1" rowspan="1">
<italic>B. animalis</italic>, <italic>B. breve</italic>, <italic>B. infantis</italic>, <italic>B. bifidum</italic>, <italic>B. lactis</italic>, <italic>B. catenulatum</italic>, <italic>B. longum</italic>, <italic>B. adolescentis</italic></td>
<td align="left" colspan="1" rowspan="1">(1) Lipoteichoic acid stimulates NO synthase<break></break>(2) Bifidobacterial proteins are one of the targets of human immunoglobulins, notably IgA<break></break>(3) Although no specific host receptors have been found, EPS has been recognized as an effector of the interaction between probiotics and the host immune system<break></break>(4) <italic>Bifidobacteria</italic> possess genomes with high G+C proportions, and unmethylated CpG motifs derived from them can interact with the TLR 9 present on immune cells<break></break>(5) The peptidoglycan hydrolase TgaA is shown to induce IL-2 production in the monocyte-derived dendritic cell, the key cytokine in Treg cell expansion<break></break>(6) The specific interaction between pili and gastrointestinal mucosa</td>
<td align="center" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B144">144</xref>–<xref ref-type="bibr" rid="B146">146</xref>]</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>NO: nitric oxide; PG: peptidoglycan; LTA: lipoteichoic acid; LPS: lipopolysaccharide; EPS: exopolysaccharides.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tab2" orientation="portrait" position="float">
<label>Table 2</label>
<caption>
<p>RCT clinical trials of probiotics and FMT treatment in IBD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Researcher/country</th>
<th align="center" colspan="1" rowspan="1">Year</th>
<th align="center" colspan="1" rowspan="1">Single/multiple-center study</th>
<th align="center" colspan="1" rowspan="1">Strains of probiotics/delivery way of FMT</th>
<th align="center" colspan="1" rowspan="1">No. of enrolled patients</th>
<th align="center" colspan="1" rowspan="1">Diseases</th>
<th align="center" colspan="1" rowspan="1">Period of observation</th>
<th align="center" colspan="1" rowspan="1">Efficacy</th>
<th align="center" colspan="1" rowspan="1">Safety</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Ahmed/UK [<xref ref-type="bibr" rid="B103">103</xref>]</td>
<td align="center" colspan="1" rowspan="1">2013</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">
<italic>Lactobacillus acidophilus</italic> LA-5, <italic>Lactobacillus delbrueckii</italic> subsp. <italic>bulgaricus</italic> LBY-27, <italic>Bifidobacterium animalis subsp. lactis</italic> BB-12, and <italic>Streptococcus thermophilus</italic> STY-31</td>
<td align="center" colspan="1" rowspan="1">20</td>
<td align="center" colspan="1" rowspan="1">CD and UC</td>
<td align="center" colspan="1" rowspan="1">2 months</td>
<td align="center" colspan="1" rowspan="1">No</td>
<td align="center" colspan="1" rowspan="1">Not mentioned</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Krag/Denmark [<xref ref-type="bibr" rid="B99">99</xref>]</td>
<td align="center" colspan="1" rowspan="1">2013</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">
<italic>Lactobacillus plantarum</italic> 299v</td>
<td align="center" colspan="1" rowspan="1">74</td>
<td align="center" colspan="1" rowspan="1">UC</td>
<td align="center" colspan="1" rowspan="1">2 years</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bourreille/France [<xref ref-type="bibr" rid="B104">104</xref>]</td>
<td align="center" colspan="1" rowspan="1">2013</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">
<italic>Saccharomyces boulardii</italic>
</td>
<td align="center" colspan="1" rowspan="1">165</td>
<td align="center" colspan="1" rowspan="1">CD</td>
<td align="center" colspan="1" rowspan="1">52 weeks</td>
<td align="center" colspan="1" rowspan="1">No</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Petersen/Denmark [<xref ref-type="bibr" rid="B105">105</xref>]</td>
<td align="center" colspan="1" rowspan="1">2014</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">
<italic>Escherichia coli Nissle</italic>
</td>
<td align="center" colspan="1" rowspan="1">100</td>
<td align="center" colspan="1" rowspan="1">UC</td>
<td align="center" colspan="1" rowspan="1">7 weeks</td>
<td align="center" colspan="1" rowspan="1">No</td>
<td align="center" colspan="1" rowspan="1">Not mentioned</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fedorak/Canada [<xref ref-type="bibr" rid="B100">100</xref>]</td>
<td align="center" colspan="1" rowspan="1">2015</td>
<td align="center" colspan="1" rowspan="1">Multiple</td>
<td align="center" colspan="1" rowspan="1">4 strains of <italic>Lactobacillus</italic>, 3 strains of <italic>Bifidobacterium</italic>, and 1 strain of <italic>Streptococcus salivarius subspecies thermophilus</italic></td>
<td align="center" colspan="1" rowspan="1">119</td>
<td align="center" colspan="1" rowspan="1">CD</td>
<td align="center" colspan="1" rowspan="1">1 year</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Yoshimatsu/Japan [<xref ref-type="bibr" rid="B101">101</xref>]</td>
<td align="center" colspan="1" rowspan="1">2015</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">
<italic>Streptococcus faecalis</italic> T-110, <italic>Clostridium butyricum</italic> TO-A, and <italic>Bacillus mesentericus</italic> TO-A</td>
<td align="center" colspan="1" rowspan="1">46</td>
<td align="center" colspan="1" rowspan="1">UC</td>
<td align="center" colspan="1" rowspan="1">1 year</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tamaki/Japan [<xref ref-type="bibr" rid="B102">102</xref>]</td>
<td align="center" colspan="1" rowspan="1">2016</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">
<italic>Bifidobacterium longum</italic> 536</td>
<td align="center" colspan="1" rowspan="1">56</td>
<td align="center" colspan="1" rowspan="1">UC</td>
<td align="center" colspan="1" rowspan="1">8 weeks</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Jacob/USA [<xref ref-type="bibr" rid="B122">122</xref>]</td>
<td align="center" colspan="1" rowspan="1">2017</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">Colonoscopy</td>
<td align="center" colspan="1" rowspan="1">20</td>
<td align="center" colspan="1" rowspan="1">UC</td>
<td align="center" colspan="1" rowspan="1">4 weeks</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Meighani/USA [<xref ref-type="bibr" rid="B126">126</xref>]</td>
<td align="center" colspan="1" rowspan="1">2017</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">Colonoscopy</td>
<td align="center" colspan="1" rowspan="1">201</td>
<td align="center" colspan="1" rowspan="1">CD and UC</td>
<td align="center" colspan="1" rowspan="1">2 years</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1">Not mentioned</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Karolewska-Bochenek/Poland [<xref ref-type="bibr" rid="B124">124</xref>]</td>
<td align="center" colspan="1" rowspan="1">2017</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">Nasoduodenal tube or gastroscopy</td>
<td align="center" colspan="1" rowspan="1">10</td>
<td align="center" colspan="1" rowspan="1">CD and UC</td>
<td align="center" colspan="1" rowspan="1">2 weeks</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Goyal/USA [<xref ref-type="bibr" rid="B123">123</xref>]</td>
<td align="center" colspan="1" rowspan="1">2018</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">Upper and lower endoscopy</td>
<td align="center" colspan="1" rowspan="1">21</td>
<td align="center" colspan="1" rowspan="1">CD, UC, and IC</td>
<td align="center" colspan="1" rowspan="1">6 months</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Mintz/USA [<xref ref-type="bibr" rid="B128">128</xref>]</td>
<td align="center" colspan="1" rowspan="1">2018</td>
<td align="center" colspan="1" rowspan="1">Single</td>
<td align="center" colspan="1" rowspan="1">Colonoscopy</td>
<td align="center" colspan="1" rowspan="1">26</td>
<td align="center" colspan="1" rowspan="1">UC</td>
<td align="center" colspan="1" rowspan="1">3 months</td>
<td align="center" colspan="1" rowspan="1">Yes</td>
<td align="center" colspan="1" rowspan="1">Not mentioned</td>
</tr>
</tbody>
</table>
</table-wrap>
</floats-group>
</article>
</pmc-articleset>